Hairless protein-interacting partner complexes and methods thereto

ABSTRACT

The present invention relates to complexes of hairless protein and proteins or nucleic acids identified as interacting with hairless protein using a yeast two-hybrid assay system. Hairless protein is indispensable for mammalian hair growth. Therefore, such interacting complexes are useful for screening test compounds for inhibition or enhancement of hair growth.

CROSS REFERENCE TO RELATED APPLICATION

[0001] This application claims the benefit of U.S. Provisional Application No. 60/385,414, filed Jun. 3, 2002.

FIELD OF INVENTION

[0002] The present invention relates to hairless protein-interacting partner complexes and methods therefor. The complexes are useful for screening test agents for inhibition or enhancement of hair growth, for example.

BACKGROUND OF THE INVENTION

[0003] Removal or inhibition of unwanted hair can be cosmetically or medically desirable. Current methods for removing unwanted hair include use of hair removal creams, shaving, waxing and electrolysis. Such methods need to be repeated frequently or are time consuming and sometimes quite painful. Hair removal creams are commonly based on thioglycollates as the active ingredient such as NAIR, for example. Thioglycollates function as reducing agents at high pH by reducing disulfide bonds in hair. However, depilatory creams typically are not recommended for frequent use due to their high irritancy potential. Antiandrogens, which have been used to treat female hirsutism, may have unwanted side effects. Lasers treatments alone or in conjunction with topical formulations are generally not selective in that they result in only partial destruction of hair follicles, may be dependent upon the pigmentation of the hair, and may promote skin reaction.

[0004] Stimulation of desired hair growth also may be cosmetically or medically desirable. There are several forms of hereditary human hair loss known as alopecias. Alopecia universalis is caused by a rare inherited mutation in humans. Androgenic alopecia, or male pattern baldness, is largely the result of heredity, advancing age, and male hormone secretion, specifically the hormone dihydrotestosterone (DHT). Women are also affected by androgenic alopecia, especially those of Caucasian origin. Minoxidil has been used with some success by younger patients and patients with less hair loss. However, the degree of new hair growth is usually minimal, and the area of the scalp that is affected is usually limited. Finasteride is an orally administered inhibitor of 5 alpha-reductase, an enzyme that converts testosterone to its active metabolite DHT. Finasteride appears more effective than minoxidil in treating androgenic alopecia, however, side effects on libido, erection, and semen volume in men and fetal defects in pregnant women have been observed.

[0005] Hairless protein (HR) is an indispensable protein for mammalian hair growth and maintenance. Individuals with point mutations in HR are hairless but are in good health except for the total lack of hair. U.S. Pat. No. 6,348,348, Feb. 19, 2002, to Thompson, reports that Hr interacts directly and specifically with thyroid hormone receptor (TR) the same protein that regulates its expression. The '348 patent reports a comparison of the amino acid sequences of their human HR sequence, a human sequence published by Ahmad et al. (Science, 279, 720-724, 1998); a human sequence published by Cichon et al. (Hum. Mol. Genet., 7, 1671-1679 and erratum at 1987-1988, 1998); a rat sequence published by Thompson (J. Neurosci., 16, 7832-7840, 1996); and a mouse sequence published by Cachon-Gonzalez et al. (Proc. Natl. Acad. Sci. USA, 91, 7717-7721, 1994). WO 99/38965 reportedly provides an isolated nucleic acid that encodes human hairless protein.

[0006] Accordingly, there exists a need for selectively removing hair that is not time consuming, painful and damaging to the skin, and results in hair removal which is long lasting, and more permanent than conventional hair removal methods. There also exists a need to selectively stimulate or enhance hair growth that is equally consumer friendly. The present inventors provide herein protein and nucleic acid interacting partners of hairless protein that, together with HR, provide complexes useful for screening test agents for inhibition or enhancement of hair growth.

SUMMARY OF THE INVENTION

[0007] The present invention provides compositions of hairless protein-hairless protein interacting partner complexes (HR-IP) determined by the present inventors using a yeast two-hybrid technology. The hairless protein interacting partners provided by the present invention are listed in Table 1 and include molecules involved in cell cycle, cell differentiation, transcription, protein turnover, protein processing, RNA splicing, house keeping (metallothionein, aldolase, enolase) and mitochondrial machinery (quinone oxidoreductase, cytochrome oxidase II and 16S RRNA, for example). Thus, Hr appears to be a well-connected, multi-functional protein. In particular, the interacting partners provided by the present invention interact with a truncated portion of hairless protein (Hrt) as set forth infra.

[0008] In one embodiment, a composition of the invention comprises a mouse Hrt protein-human interacting partner protein complex wherein the human interacting partner protein comprises a molecule selected from the group consisting of ubiquitous receptor UR, SEQ ID NO:4, MAPIA, SEQ ID NO:8, KIAA0930 protein, SEQ ID NO:13, and monocyte antigen CD14. In another embodiment, the human interacting partner protein is encoded by a nucleic acid comprising SEQ ID NO:11, SEQ ID NO:90, or SEQ ID NO:99.

[0009] In another embodiment, a composition of the invention comprises a mouse Hrt protein-human interacting partner protein complex wherein the human interacting partner protein comprises a molecule selected from the group consisting of sphingolipid activator protein, beta-synuclein, C11 protein, vesicle-associated membrane protein 2, SEQ ID NO:25, aldolase A, CGI106 protein, hypothalamus protein HSMNP1, alpha enolase, SEQ ID NO:35, POM-ZP3, SEQ ID NO:39, quinone oxidoreductase, SEQ ID NO:43, pumilio 1, VPS41, and KIAA0614 protein. In a further embodiment, the invention provides a composition comprising a mouse Hrt protein-human interacting partner nucleic acid complex wherein the human interacting partner nucleic acid comprises SEQ ID NO:95.

[0010] A composition comprising a mouse Hrt protein-human interacting partner protein complex where the human interacting partner protein comprises a molecule selected from the group consisting of SEQ ID NO:52, SEQ ID NO:54; SEQ ID NO:58, splicing factor CC1.4, SEQ ID NO:65, SEQ ID NO:67, ubiquitin, beta-mannosidase, SEQ ID NO:85, and SEQ ID NO:87 is a further embodiment of the invention. In a further embodiment, the human interacting partner protein is encoded by a nucleic acid comprising SEQ ID NO:50, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:61, SEQ ID NO:62; SEQ ID NO:63, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:82, SEQ ID NO:88, SEQ ID NO: 89, or SEQ ID NO:91.

[0011] A further embodiment of the invention is a composition comprising a mouse Hrt protein-human interacting partner nucleic acid complex wherein the human interacting partner nucleic acid comprises SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, or SEQ ID NO:98.

[0012] A method of assaying a test compound for agonist or antagonist activity for a composition set forth herein comprises a) measuring a level of interaction between mouse Hrt protein and the human interacting partner in the absence of the test compound; b) measuring a level of interaction between mouse Hr protein and the human interacting partner in the presence of the test compound; wherein when the level measured in step b) is greater than the level in step a), the test compound has agonist activity, and wherein when the level measured in step b) is less than the level in step a), the test compound has antagonist activity.

[0013] A further embodiment of the invention is a method of inhibiting hair growth on a surface in a subject in need thereof, comprising applying to the surface a growth-inhibiting amount of a compound having antagonist activity for a composition herein for a time sufficient to inhibit hair growth on the surface.

[0014] Another embodiment of the invention is a method of increasing hair growth on a surface in a subject in need thereof, comprising applying to the surface a growth-increasing amount of a compound having agonist activity for a composition herein for a time sufficient to increase hair growth on the surface. Types of alopecias that may be treated by agents that enhance hairless protein-interacting partner complexes include androgenetic alopecia (male pattern baldness), alopecia areata, alopecia universalis, congenital alopecia universalis.

[0015] All documents cited are, in relevant part, incorporated herein by reference; the citation of any document is not to be construed as an admission that it is prior art with respect to the present invention.

DETAILED DESCRIPTION OF THE INVENTION

[0016] A modified, improved yeast two-hybrid system was used to identify protein interaction partners with hairless protein (HR-IP). The yeast two-hybrid system, in general, measures the association of two fusion proteins expressed in yeast. Interaction discovered in yeast is indicative of potential interaction that would occur under physiological conditions.

[0017] By “hairless protein (HR)” is meant herein the mouse hairless protein. By “truncated hairless protein (HRt)” is meant the sequence provided as SEQ ID NO:103 which is amino acid residues 490-1182 of the C-terminal portion of mouse HR protein. Derivatives, fragments, or analogs of HR known to one of skill in the art in light of the present disclosure are considered equivalents of HR. An antagonist or agonist having activity for HRt is expected to also have activity for HR. Since mouse HR is greater than 80% identical to human HR, the interacting partners provided herein are expected to interact with human hairless protein. Antagonists or agonists of the present HRt-IP complexes are expected to have activity for human hairless protein interacting partner equivalents.

[0018] By “interacting partner (IP)” is meant a protein or nucleic acid that has sufficient binding affinity for HRt so that, when the IP and HRt are fused to separate constituents of a transcriptional regulator, the HRt-IP affinity is sufficient to allow reconstitution of the constituents of the transcriptional regulator thereby providing an activated regulator. The interaction may occur due to specific electrostatic, hydrophobic, hydrophilic, entropic or other interaction of certain portions of HRt with certain portions of IP to form a stable complex under conditions effective to promote the interaction. Interacting partners are identified by the data provided in Table 1. That is, the identity of the interacting partner was determined by homology searching using nucleotide sequence data from positive results in the yeast two-hybrid system. Derivatives, fragments, or analogs of interacting partners identified in Table 1 known to one of skill in the art in light of the present disclosure are considered equivalents of interacting partners.

[0019] By “HRt-IP complex” is meant at least one molecule of HRt associated with at least one molecule of interacting partner, under physiological conditions of ionic strength, temperature, pH and the like. The complex may be in vivo or in vitro.

[0020] In the yeast two-hybrid system, transcription of a reporter gene (e.g., gal4) is dependent upon reconstitution of a gal 4 regulator by the interaction of two proteins, each fused to “half” of the regulator. When the two proteins have sufficient binding affinity to interact, the interaction results in the reconstitution of the gal 4 regulator which then activates transcription of the reporter gene. “Half” of the regulator is a DNA binding domain (BD), and “half” of the regulator is an activation domain (AD). When a “bait” protein is fused to the binding domain, and a “prey” protein is fused to the activator domain, or vice versa, sufficient binding affinity of the “bait” and “prey” proteins allow reconstitution of BD and AD to allow the reporter gene to be activated. Such an assay therefore is a test for affinity between the “bait” and “prey” proteins. The yeast two hybrid technology has been described in, for example, U.S. Pat. No. 5,986,055, Nov. 16, 1999 to Yang, M., et al., incorporated by reference herein.

[0021] In the present invention, the “bait” protein is a C-terminal portion of hairless protein of mouse (HRt) having amino acid residues 490 to 1182 (provided as SEQ ID NO:103, the nucleic acid sequence encoding amino acids 490-1182 is provided as SEQ ID NO:102) “Structure and Expression of the Hairless Gene of Mice,” Begona, M., et al., J. Proc. Natl. Acad. Sci, USA 91:7717-7721, 1994) (GenBank accession no. Z32675).

[0022] In the present invention, the “prey” protein is a human brain cDNA library. When two complimentary mating types of yeast, one containing the BD-HRt fusion protein, and the other containing the AD-human cDNA protein, are mated, the progeny express each fusion protein. Those cDNA proteins having sufficient affinity for HRt will bind HRt and allow the BD and AD to reconstitute to activate a reporter gene. Therefore, positive results from the two-hybrid system demonstrate affinity and interaction between the mouse HRt and a human protein.

[0023] Since mouse Hr is greater than 80% identical to human HR, the present inventors would expect with reasonable certainty that the human proteins that interact with mouse HRt provided by the present invention would also interact with human HRt. Similarly, test-compounds that prove to be agonists or antagonists of a mouse HRt-human interacting partner interaction are expected by the present inventors to be agonists or antagonists of the human HRt-human interacting partner.

[0024] In addition to providing HRt-human interacting protein complexes, the assay used herein resulted in certain positive results for untranslated 3′ regions of DNA as well as to RNA. While not wanting to be bound by theory, the present inventors believe that BD-HRt may bind mitochondrial 16S rRNA, for example, and that interaction may cause transcriptional activation (for example, 16S rRNA present close to promoter by virtue of its interaction with BD-HRt may as such or through its secondary interaction with a yeast transcriptional activator may activate transcription.

[0025] By an “antagonist” of HR-IP interaction is meant an agent having inhibitory activity for the binding of the HR-IP complex. The binding may be inhibited by an effect on the interaction between HR and IP, or by an effect on HR or IP that affects the interaction between HR and IP.

[0026] By an “agonist” of HR-IP interaction is meant an agent having enhancing or stimulatory activity for the binding of the HR-IP complex. The binding may be stimulated by an effect on the interaction between HR and IP or by an effect on HR or IP that affects the interaction between HR and IP. Identification of an antagonist or an agonist is made by allowing HR and IP to interact in the presence of a test agent. A decrease or increase in HR-IP interaction relative to the interaction when the test agent is absent indicates that the test agent has an effect on the interacting pair as further described infra.

[0027] In HR-interacting partner protein compositions of the present invention, conservative amino acid substitutions, such as Glu/Asp, Val/Ile, Ser/Thr, Arg/Lys and Gln/Asn, would be considered equivalent since the chemical similarity of these pairs of amino acid residues would be expected to result in functional equivalency. Amino acid substitutions that conserve the biological function of the HR-interacting partner protein would conserve such properties as hydrophobicity, hydrophilicity, side-chain charge, or size. Functional equivalency is determined by the interaction of the equivalent pair as compared to the native pair. Included within the scope of the invention are complexes of HR-interacting protein fragments, derivatives, or analogs that are modified during or after translation, e.g., by glycosylation, acetylation, phosphorylation, amidation, fatty acylation, sulfation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, or the like.

[0028] In HR-interacting partner nucleic acid compositions of the present invention, a molecule that is the complement of a nucleic acid molecule that hybridizes to the interacting partner nucleic acid under stringent hybridization conditions would be considered equivalent since such a molecule is expected to result in functional equivalency as an interacting partner nucleic acid. Functional equivalency is determined by the interaction of the equivalent pair as compared to the native pair. Stringency conditions for hybridization depend upon a number of factors such as the length of hybridizing molecules, salt concentration, temperature, and the presence or absence of denaturing agents, for example. High stringency conditions may include hybridization at about 42° C. and about 50% formamide, 0.1 mg/mL sheared salmon sperm DNA, 1% SDS, 2×SSC, 10% Dextran sulfate, a first wash at about 65° C., about 2×SSC, and 1% SDS, followed by a second wash at about 65° C. and about O. 1×SSC. Alternatively, high stringency conditions may include hybridization at about 42° C. and about 50% formamide, 0.1 mg/mL sheared salmon sperm DNA, 0.5% SDS, 5×SSPE, 1× Denhardt's, followed by two washes at room temperature and 2×SSC, 0.1% SDS, and two washes at between 55-60° C. and 0.2×SSC, 0.1% SDS.

[0029] HR-IP complexes may be used for preparation of polyclonal or monoclonal antibodies, antibody fragments, humanized antibodies, single chain antibodies for affinity purification, detection or other functional studies. Methods for producing antibodies are well known in the art and can be applied to HR-IP complexes in light of the present disclosure. Antibodies having binding specificity for the HR portion or the IP portion of the HR-IP complex may be removed from an anti-HR-IP preparation by adsorption with HR or with the IP. Remaining antibodies will have specificity for the complex.

[0030] Screening for Antagonists or Agonists of HR-IP Complexes

[0031] HR-IP complexes or nucleic acids encoding HR-IP complexes may be used to screen for compounds that bind to HR-IP complexes and thus, such compounds have use as agonists or antagonists of HR-IP complexes. The invention therefore provides assays to detect molecules that either enhance or inhibit interaction of HR and an interacting partner. Such molecules may be small molecules, peptides, modified peptides, aptamers, nucleic acids, or modified nucleic acids, for example. A molecule that modulates activity of HR-IP is identified by contacting a test molecule either with HR or with IP prior to contacting HR and IP together, or allowing a three way binding among HR, IP and the test molecule. Modulation of HR-IP interaction may be measured by measuring the stability of the complex, the affinity or binding of the complex, rate of formation of the complex, the amount of complex, or another function of the complex. An increase or decrease in any of these parameters relative to the parameter in the absence of the test molecule indicates that the test molecule is an agonist or an antagonist of the complex. Methods for identifying such agonists or antagonists may be carried out using the modified yeast two-hybrid assay described herein, or may be carried out in vitro, for example.

[0032] Test agents to be screened for antagonist or agonist activity may be provided as mixtures of specified compounds, or as compound libraries, peptide libraries, antisera, antisense nucleic acids, random or combinatorial libraries, chemically synthesized libraries, recombinant libraries, or in vitro translation-based libraries. Agents may be screened for activity as competitive or non-competitive inhibitors of HR-IP interaction. In particular, fragments or analogs of HR or the IP may be screened for such inhibitory activity. Agents may be screened for inhibition or enhancement of binding of HR and IP under aqueous or physiological binding conditions in which HR-IP binding occurs in the absence of the agent to be tested. Agents that lessen the binding are identified as antagonists of the complex, and agents that enhance the binding are identified as agonists of the complex.

[0033] Typical binding conditions are, for example, an aqueous solution of 10-250 mM NaCl, 5-50 mM Tris-HCl, pH 5-8, 0.5% Triton X-100. Metal chelators or divalent cations may be added to improve binding. Binding temperatures may include that of an ice bath up to 42 degrees C. The time of incubation is sufficient to allow binding equilibrium to occur. Methods known to one of skill in the art in light of the present disclosure may be used to assay for binding between HR and an interacting partner and a test agent, including use of detectable labels and quantification of complex formation.

[0034] A yeast two-hybrid assay system may be used to test an agent for antagonist or agonist activity for HR-IP binding similar to the assay system set forth by U.S. Pat. No. 5,986,055, Nov. 16, 1999, for CDK2-interacting proteins, incorporated by reference herein. The two-hybrid assay is carried out as described in the present examples, except that it is done in the presence of a test agent. An increase or decrease in reporter gene activity relative to that present when the test agent is absent indicates that the test agent has an effect on the interacting pair.

[0035] Components of such a system include a reconstitutable transcriptional regulator and a reporter gene. The reconstitutable transcriptional activator comprises a DNA binding domain (BD) and an activator domain (AD) that, when reconstituted, induces transcription of the reporter gene. The nucleotide sequence encoding HRt, fragment, derivative, or analog thereof is fused to either the DNA binding domain or the activator domain, and the nucleotide sequences encoding an interacting partner identified from the data of Table 1 is fused to the other of the BD or AD. The DNA binding domain can be any DNA binding domain, as long as it specifically recognizes a DNA sequence within a promoter active for a reporter gene. The activator domain has activity for the binding domain of the transcriptional regulator. The reporter gene is operably linked to a promoter that contains a binding site for the DNA binding domain. As for example, binding of BD-HR to AD-IP leads to reconstitution of the BD-AD transcriptional regulator that activates expression of the reporter gene. The activation of transcription of the reporter gene occurs intracellularly, e.g., in prokaryotic or eukaryotic cells, preferably in cell culture. The reporter gene encodes a detectable marker molecule that can give rise to a detectable signal, e.g., a fluorescent protein or a protein that can be readily visualized or that is recognizable by a specific antibody or an enzyme such as LacZ or α-galactosidase and is readily assayed.

[0036] Strains of yeast are chosen for selectable markers that confer ability to grow under conditions that do not support the growth of cells not expressing the selectable marker, e.g., the selectable marker is an enzyme that provides an essential nutrient and the cell in which the interaction assay occurs is deficient in the enzyme and the selection medium lacks such nutrient. The reporter gene is under the control of the native promoter that naturally contains a binding site for the DNA binding protein, or under the control of a heterologous or synthetic promoter.

[0037] Examples of transcriptional regulator proteins that have separable binding and transcriptional activation domains include, for example, the GAL4, the GCN4, and the ARD1 proteins of S. cerevisiae and the human estrogen receptor. The DNA binding domain and activation domain that are employed in the fusion proteins need not be from the same transcriptional regulator. For example, a GAL4 or a LEXA DNA binding domain is employed, or a GAL4 or herpes simplex virus VPI6 activation domain is employed. In one embodiment, the yeast transcription factor GAL4 is reconstituted by the protein-protein interaction and the host strain is mutant for GAL4. Other embodiments are known to one of skill in the art in light of the present disclosure.

[0038] To facilitate isolation of the encoded interacting partners, the fusion constructs can further contain sequences encoding affinity tags such as glutathione-S-transferase or maltosebinding protein or an epitope of an HR or HRt antibody, for affinity purification for binding to the HR-IP. Where the IP is a nucleic acid, an affinity tag may be a hybridizing nucleotide sequence complementary to the nucleic acid IP.

[0039] The host cell in which the interaction assay occurs can be any cell, prokaryotic or eukaryotic, in which transcription of the reporter gene can occur and be detected, including but not limited to mammalian (e.g., monkey, chicken, mouse, rat, human, bovine), bacteria, and insect cells, and is preferably a yeast cell. Expression constructs encoding and capable of expressing the binding domain fusion proteins, the transcriptional activation domain fusion proteins, and the reporter gene product are provided within the host cell, by mating of cells containing the expression constructs, or by cell fusion, transformation, electroporation, or microinjection, for example. The host cell used should not express an endogenous transcription factor that binds to the same DNA site as that recognized by the DNA binding domain fusion population. In addition, the host cell is mutant or otherwise lacking in an endogenous, functional form of the reporter gene used in the assay.

[0040] Various vectors and host strains for expression of the two fusion protein populations in yeast are known and can be used (see, e.g., U.S. Pat. No. 5,986,055, Nov. 16, 1999). For example, yeast strains or derivative strains made therefrom, which can be used are N105, N106, N1051, N1061, and YULH, Y190: MATa, ura3-52, his3-200, Iys2-801, ade2-101, trp1-901, leu2-3,112, gal4.DELTA., gal80.DELTA., cyh.sup.r 2, LYS2::GAL1.sub.UAS-HIS3.sub.TATA HIS3, URA3::GAL1.sub.UAS-GAL1.sub.TATA-lacZ. CG-1945: MATa, ura3-52, his3-200, lys2-801, ade2-101, trp1-901, leu2-3,112, gal4-542, gal80-538, cyh.sup.r 2, LYS2::GAL1.sub.UAS HIS3.sub.TATA HIS3, URA3::GAL1.sub.UAS17mers(×3)-CYC1.sub.TATA-lacZ. Y187: MAT.alpha., ura3-52, his3-200, ade2-101, trp1-901, leu2-3,112, gal4.DELTA., gal80.DELTA., URA3::GAL1.sub.UAS-GAL1.sub.TATA-lacZ. SFY526: MATa, ura3-52, his3-200, lys2-801, ade2-101, trp1-901, leu2-3,112, gal4-542, gal80-538, can.sup.r, URA3::GAL1-lacZ. HF7c: MATa, ura3-52, his3-200, lys2-801, ade2-101, trp1-901, leu2-3,112, gal4-542, gal80-538, LYS2::GAL1-HIS3. URA3::GAL1.sub.UAS17MERS(×3)-CYC1-lacZ. YRG-2: MATa, ura3-52, his3-200, lys2-801, ade2-101, trp1-901, leu2-3,112, gal4-542, gal80-538 LYS2::GAL1.sub.UAS-GAL1.sub.TATA-HIS3, URA3::GAL1.sub.UAS 17mers(×3)-CYC1-lacZ.

[0041] Plasmids are capable of autonomous replication in a host yeast cell and preferably are capable of being propagated in E. coli. The plasmid contains a promoter directing the transcription of the DNA binding or activation domain fusion genes, and a transcriptional termination signal. The plasmid also preferably contains a selectable marker gene, permitting selection of cells containing the plasmid. The plasmid can be single-copy or multi-copy. Single-copy yeast plasmids that have the yeast centromere may also be used to express the activation and DNA binding domain fusions. In another embodiment, the fusion constructs may be introduced directly into the yeast chromosome via homologous recombination using methods known to one of skill in the art in light of the present disclosure.

[0042] Plasmids encoding the separate fusion proteins can be introduced into a single host cell (e.g., a haploid yeast cell) containing one or more reporter genes, by co-transformation, to conduct the assay for HRt-IP interactions. Alternatively, the two fusion proteins are introduced into a single cell by mating (e.g. for yeast cells) or cell fusions (e.g., of mammalian cells). In a mating type assay, conjugation of haploid yeast cells of opposite mating type that have been transformed with a binding domain fusion expression construct and an activation domain fusion expression construct, respectively, delivers both constructs into the same diploid cell. The mating type of a yeast strain may be manipulated by transformation with the HO gene.

[0043] In one embodiment, a yeast interaction mating assay is employed, using two different types of host cells, strain-types a and alpha, of the yeast Saccharomyces cerevisiae. One set of host cells, for example the a strain cells, contains fusions of the HRt nucleotide sequences with the DNA-binding domain of a transcriptional activator, such as GAL4. The hybrid proteins expressed in this set of host cells are capable of recognizing the DNA-binding site on the reporter gene. The second set of yeast host cells, for example alpha strain calls, contains nucleotide sequences as identified by the data provided in Table 1 fused to the activation domain of a transcriptional activator. In one embodiment, the fusion protein constructs are introduced into the host cell as a set of plasmids.

[0044] Bacteriophage vectors may be used to express the DNA binding domain and/or activation domain fusion proteins. Libraries can generally be prepared faster and more easily from bacteriophage vectors than from plasmid vectors.

[0045] Reporter genes include URA3, HIS3, lacZ, MEL1, GFP, luciferase, LEU2, LYS2, ADE2, TRP1, CAN1, CYH2, GUS, CUP1, or CAT, for example. Expression of LEU2, LYS2, ADE2 and TRP1 are detected by growth in a specific defined media; GUS, lacZ, MEL1, and CAT can be monitored by well known enzyme assays; and CAN1 and CYH2 are detected by selection in the presence of canavanine and cycloheximide. The natural fluorescence of GFP is detected. In another embodiment, transcription of the reporter gene is detected by a linked replication assay known to those of skill in the art in light of the present disclosure. In another embodiment, the expression of a reporter gene is detected by immunoassay. Activity of the reporter gene lacZ is monitored by measuring a detectable signal, such as X-gal (5-bromo-4-chloro-3-indolyl-.alpha.-D-galactoside).

[0046] False positives arising from transcriptional activation by the DNA binding domain fusion proteins in the absence of a transcriptional activator domain fusion protein are prevented or reduced by negative selection.

[0047] In one embodiment of the invention, the DNA sequences encoding the pairs of interacting partners are isolated by amplification in separate respective reactions. Amplification is carried out by polymerase chain reaction known by one of skill in the art using pairs of oligonucleotide primers specific for either the DNA-binding domain hybrids or the activation domain hybrids. Other amplification methods known in the art can be used, including but not limited to ligase chain reaction, use of Q beta. replicase, or the like.

[0048] Purification of HR-IP complexes

[0049] HR-IP complexes may be isolated and purified by standard methods known in the art from natural sources or recombinant host cells expressing the complexes, including but not limited to column chromatography (e.g., ion exchange, affinity, gel exclusion, reverse-phase high pressure, fast protein liquid, and the like), differential centrifugation, differential solubility, or by other standard techniques used in purification of protein complexes or protein-nucleic acid complexes.

[0050] The amino acid sequence of an interacting protein can be deduced from the nucleic acid sequence of the chimeric gene from which it was encoded. As a result, the protein or a derivative thereof can be synthesized by standard chemical or recombinant methods known in the art.

[0051] Formulations for Agonists or Antagonists of HR-IP and Administration Thereof

[0052] The concentration of an antagonist active or an agonist active, identified by methods of the present invention, in a composition may be varied over a wide range up to a saturated solution, preferably from 0.01% to 99% by weight. The maximum amount effectively applied is limited by the rate at which the active penetrates the skin. Generally, the effective amount ranges from 100 micrograms to 3000 micrograms per square centimeter of skin. The composition may be applied once or twice a day, or even more frequently, for a period of time of 2 weeks to 6 months to achieve a perceived effect on hair growth.

[0053] The composition may be administered topically by any convenient means. Topical compositions that can be applied locally to the skin may be in a form such as a solution, an oil, cream, ointment, gel, lotion, shampoo, leave-on and rinse-out hair conditioner, milk, cleanser, moisturizer, spray, skin patch, or the like.

[0054] The composition may include a non-toxic dermatologically acceptable vehicle or carrier that is adapted to be spread on the skin. Examples of suitable vehicles are acetone, alcohols, or a cream, lotion or gel that can effectively deliver the active compound. In addition, a penetration enhancer may be added to the vehicle to further enhance the effectiveness of the formulation.

[0055] A composition containing an HR-IP antagonist should be applied to an area of the body where it is desired to inhibit hair growth. A composition containing an HR-IP agonist should be applied to an area of the body where it is desired to enhance hair growth. For example, a woman may choose to inhibit hair growth on her face, arm-pits, or legs whereas a man may choose to enhance hair growth on his face, particularly to a balding area, a beard area, i.e., the cheek, neck, upper lip, or chin. An inhibitory composition may also be applied to the legs, arms, torso, bikini line, or armpit, for example. An inhibitory composition is particularly suited for hirsutism. A man may also wish to use an HR-IP antagonist as a “shaveless” product with the purpose of reducing the frequency of shaving.

[0056] Reduction of hair growth is demonstrated when the frequency of hair removal is reduced, or the subject perceives less hair on the treated site, or when the weight of hair removed by shaving is reduced. Conversely, enhancement of hair growth is demonstrated when the subject perceives more hair on the treated site, or when the weight of hair removed by shaving is increased as compared to a control.

[0057] One of ordinary skill in the art would be able to select appropriate adjunct ingredients and amounts to formulate in the compositions described above without undue experimentation, depending on the compound selected and the intended use of the composition. Suitable adjunct ingredients in topical compositions include carriers comprising one or more ingredients selected from the group consisting of i) emollients, ii) solvents, iii) humectants, iv) thickeners, v) powders, vi) perfumes, vii) waxes, viii) preservatives, ix) surfactants, x) bases, xi) penetration enhancers and others in addition to, or instead of, the adjunct ingredients listed above.

[0058] Ingredient i) is an emollient. The amount of ingredient i) in the composition is typically about 5 to about 95%. Suitable emollients include stearyl alcohol, glyceryl monoricinoleate, glyceryl monostearate, propane-1,2-diol, butane-1,3-diol, mink oil, cetyl alcohol, isopropyl isostearate, stearic acid, isobutyl palmitate, isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecan-2-ol, isocetyl alcohol, cetyl palmitate, di-n-butyl sebacate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, butyl stearate, polyethylene glycol, triethylene glycol, lanolin, sesame oil, coconut oil, arachis oil, castor oil, acetylated lanolin alcohols, mineral oil, butyl myristate, isostearic acid, palmitic acid, isopropyl linoleate, lauryl lactate, myristyl lactate, decyl oleate, myristyl myristate, polydimethylsiloxane, petrolatum, and combinations thereof. Preferred emollients include stearyl alcohol, polydimethylsiloxane, and petrolatum.

[0059] Ingredient ii) is a solvent. The amount of ingredient ii) in the topical composition is typically about 5 to about 95%. Suitable solvents include water, ethyl alcohol, benzyl alcohol, isopropyl alcohol, castor oil, ethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether, and combinations thereof. Preferred solvents include water and benzyl alcohol.

[0060] Ingredient iii) is a humectant. The amount of ingredient iii) in the composition is typically about 2 to about 95%. Suitable humectants include glycerol, polyoxyalkylene glycols, sodium polyaspartate, methacryloyloxyethylphosphorylcholine copolymers, sodium hyaluronate, chitosan, glycerol, sorbitol, sodium 2-pyrrolidone-5-carboxylate, soluble collagen, dibutyl phthalate, gelatin, and combinations thereof. Preferred humectants include glycerol and sodium 2-pyrrolidone-5-carboxylate.

[0061] Ingredient iv) is a thickener. The amount of ingredient iv) in the composition is typically to about 95%. Thickeners include poly(acrylic acid), poly(vinyl alcohol), hydroxyethyl cellulose, methyl cellulose, carbomer [poly(acrylic acid crosslinked with polyalkenyl polyether], acrylamide copolymer, carboxymethyl starch, and combinations thereof.

[0062] Ingredient v) is a powder. The amount of ingredient v) in the composition is typically 0 to about 95%. Suitable powders include chalk, talc, fullers earth, kaolin, starch, gums, colloidal silicon dioxide, sodium polyacrylate, tetraalkyl ammonium smectites, trialkyl aryl ammonium smectites, chemically modified magnesium aluminum silicate, organically modified montmorillonite clay, hydrated aluminum silicate, fumed silica, carboxyvinyl polymer, sodium carboxymethyl cellulose, ethylene glycol monostearate, and combinations thereof.

[0063] Ingredient vi) is a perfume, as described above. The amount of ingredient vi) in the topical composition is typically about 0.001 to about 0.5%, preferably about 0.001 to about 0.1%.

[0064] Ingredient vii) is a wax. Waxes useful in this invention are selected from the group consisting of animal waxes, vegetable waxes, mineral waxes, various fractions of natural waxes, synthetic waxes, petroleum waxes, ethylenic polymers, hydrocarbon types such as Fischer-Tropsch waxes, silicone waxes, and mixtures thereof wherein the waxes have a melting point between 40 and 100° C. The amount of ingredient vii) in the composition is typically about 1 to about 99%.

[0065] Ingredient viii) is a preservative such as phenol, alkyl esters of parahydroxybenzoic acid, benzoic acid and the salts thereof, boric acid and the salts thereof, sorbic acid and the salts thereof, chorbutanol, benzalkonium chloride, cetylpyridinium chloride, and parabens such as methyl paraben, ethyl paraben, and propyl paraben. Particularly preferred are the salts of benzoic acid, cetylpyridinium chloride, methyl paraben, and sodium benzoate. The amount of ingredient viii) in the composition is typically about 1 to about 99%.

[0066] Ingredient ix) is a surfactant. Suitable surfactants include lecithin, polysorbate 80, sodium lauryl sulfate, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene monoalkyl ethers, sucrose monoesters, lanolin esters, lanolin ethers, and combinations thereof. Suitable surfactants are known in the art and commercially available, e.g., the TWEENS® from Atlas Powder Company of Wilmington, Del. and PEMULEN® TR-2 available from B.F. Goodrich Company of Charlotte, N.C. Suitable surfactants are disclosed in the C.T.F.A. Cosmetic Ingredient Handbook, pp.587-592 (1992); Remington: The Science and Practice of Pharmacy, 19th Ed., p. 239, 250, 1501 (1995); and McCutcheon's Volume 1, Emulsifiers & Detergents, North American Edition, pp. 236-239 (1994). The amount of ingredient ix) in the composition is typically about 1 to about 99%.

[0067] Ingredient x) is a base for adjusting the pH of the formulation. A suitable base to be used is an inorganic base, for example, sodium hydroxide, potassium hydroxide, an alkali metal oxide such as sodium or potassium oxide, ammonia, ammonium carbonate, K₂CO₃, Na₂CO₃, or an organic base such as an alkanolamines (as e.g. monoethanolamine). Typical levels of such bases, when present, are about 0.01% to about 2.0%.

[0068] Ingredient xi) is a penetration enhancer for enhancing the penetration of the actives into the skin or to the site of action. Examples of penetration enhancers include urea, propan-2-ol, polyoxyethylene ethers, terpenes, cis-fatty acids such as oleic acid or palmitoleic acid, acetone, laurocapram dimethyl sulfoxide, 2-pyrrolidone, oleyl alcohol, glyceryl-3-stearate, cholesterol, myristic acid isopropyl ester, or propylene glycol, for example. The amount of ingredient xi) in the composition is typically about 1 to about 99%. The composition also can be formulated to provide a reservoir within or on the surface of the skin to provide for a continual slow release of the active. The composition also may be formulated to evaporate slowly from the skin, allowing the active extra time to penetrate the skin.

EXAMPLE 1 Interaction Partners (IP's) of Hairless Protein

[0069] The present example provides for Hairless Protein (HR) interacting partners (HR-IP) using the yeast two-hybrid technology. HR cDNA corresponding to the C-terminal half of HR protein (aa residues 490 to 1182, hereinafter HRt) is cloned into a yeast two hybrid binding domain (BD) vector so as to express BD-HRt in yeast. Yeast cells expressing BD-HRt are mated with yeast cells pretransformed with human brain cDNA library in the activation domain (AD) vector. The resultant interacting partners provided by the present invention are listed in Table 1 and include molecules involved in cell cycle, cell differentiation, transcription, protein turnover, protein processing, RNA splicing, house keeping (metallothionein, aldolase, enolase) and mitochondrial machinery (quinone oxidoreductase, cytochrome oxidase II and 16S rRNA, for example). Thus, HR (and HRt) appears to be a well-connected, multi-functional protein.

[0070] Materials: A mouse early anagen cDNA library is constructed by personnel at Procter & Gamble using standard techniques. E. coli expression plasmid pET32a (Catalog No. 69015-3; component plasmid of Novagen's pET prokaryotic expression system) and E. coli strain BL21(DE3) competent cells (Catalog No. 69387-3) are purchased from Novagen (Madison, Wis.). Custom designed oligonucleotides are synthesized by personnel at Procter & Gamble using standard techniques or made by BD Biosciences Clontech (PaloAlto, Calif.). DNA sequence determination is performed by personnel at Procter & Gamble using standard techniques or contracted out to Seqwright Inc (Houston, Tex.). DNA sequence analyses and data base searches for homology are performed using SeqWeb version 1.2 (in conjunction with Wisconsin Package Version 10.1). Various microbiological media are purchased from BD Biosciences Clontech (PaloAlto, Calif.) and DIFCO Becton Dickinson Microbiology Systems (Sparks, Md.). Various premade media plates for cultivation of E. coli and yeast are purchased from Gibson Laboratories (Lexington, Ky.). Matchmaker two-hybrid System 3 (Catalog No. K1612-1), pre-transformed human brain Matchmaker cDNA library in pACT2 vector (Catalog No.HY4004AH, Lot No.9070550), Advantage 2 PCR kit (catalog No. K1910-1), and Matchmaker AD LD-insert screening amplimer sets (Catalog No. 9103-1), are purchased from BD Biosciences Clontech (PaloAlto, Calif.). Male mice (C3H strain) are purchased from Harlan Labs (Indianapolis, Ind.). NAIR lotion hair remover (4 minute formula) is purchased from a local Walgreens store. Dolgel Gel (5% ibuprofen) is purchased from Life Extension International Center Inc. (Coral Gables, Fla.). Restriction enzymes, T4 DNA ligase, molecular weight markers, agarose, and other routine molecular biology reagents are purchased from Life Technologies (Gaithersburg, Md.).

[0071] Cloning and characterization of mouse Hairless (HR) cDNA: Oligonucleotides are designed to PCR-amplify the desired portion of mouse HR cDNA, based on the published sequence for mouse HR “Structure and Expression of the Hairless Gene of Mice,” Begona, M., et al., J. Proc. Natl. Acad. Sci, USA 91:7717-7721, 1994) (GenBank accession no. Z32675). The oligonucleotides are also designed to contain restriction enzyme recognition sites for Eco RI, Xba I, Not I and Bam HI restriction enzymes for subsequent manipulation of the PCR product. In particular, the restriction enzyme sites for Eco RI and Not I (noted as underlined and italicized in the oligonucleotides shown below) are particularly useful for subsequent cloning and manipulation. The forward and reverse oligonucleotide primer pairs 5′-CCG GAA TTC GTC ACC CAG TGC CAA AGC TGT (SEQ ID NO:100) and 5′-CGG GAT CCT CTA GAG CGG CCG CTT ATT ATT TAG CTT CCT GTA ACG CCCC (SEQ ID NO:101) are used to PCR amplify HR cDNA corresponding to nucleotides 1845-3923 of HR from mouse early anagen cDNA library. PCR amplification is performed using the standard PCR protocol supplied with the Advantage 2 PCR kit. The PCR product is analyzed by agarose gel electrophoresis and is found to have the expected size (approximately 2 Kb). The PCR product is excised with Eco RI and Not I restriction enzymes. The restricted product is gel-purified and inserted into Eco RI and Not I sites of pET32a, such that the insert makes an in-frame fusion with upstream sequences. The resulting plasmid is designated pET32a-HRt. This plasmid is used for both nucleotide sequence confirmation as well as for protein expression in E. coli. The nucleotide sequence reveals changes at three positions (nucleotide position 2166, change from C to T causing a codon change from AGC to AGT; nucleotide position 2611, change from C to T causing a codon change from GAC to GAT; nucleotide position 2916, change from T to C causing a codon change from CCT to CCC) from the published sequence (SEQ ID NO:102). Amino acid number 1 of SEQ ID NO:103 corresponds to amino acid residue 490 of the C-terminal portion of HR protein. This truncated HR(HRt) cDNA corresponds to amino acid residues 490-1182 of the C-terminal portion of HR protein.

[0072] However, none of the above-cited changes results in an amino acid change. In essence the HRt cloned herein is predicted to code for a protein product identical to that of mouse HRt. The zinc finger region (amino acids 595-620) and three PEST domains are present in the 490-1182 amino acid portion of Hr. The PEST domains (region 522-546 having a score of 12.26, region 709-722 having a score of 7.56, and region 729-744 having a score of 21.71) are expected by the present inventors to be important in Hr function. Mouse HR is greater than 80% identical to human HR. PEST sequences are often found to serve as signals for rapid protein degradation. PEST sequences are constitutive or conditional signals. Constitutive means “as such,” while conditional means “upon modification” (such as phosphorylation, cis-trans isomerisation induced by light, ligand binding, etc.). To objectively determine whether a protein contains a PEST region, a computer program called PEST-FIND has been developed by M. Rechsteiner and S. W. Rogers (PEST Sequences and Regulation by Proteolysis, TIBS 21, July 1996). The algorithm, which is available in PC/GENE (OMIGA), defines a PEST sequence as a hydrophilic stretch of 12 or more amino acid residues containing at least one each of Pro, Glu/Asp, and Ser/Thr in any order or combination. They also have to be flanked by basic amino acid residues Lys, Ala, or His, but basic residues are disallowed within the PEST sequence. PEST-FIND produces a score ranging from about +50 to −50. By definition, a score >0 denotes a possible PEST region, but a value >+5 indicates a highly probable PEST region. The PEST regions noted herein also have numerous potential protein kinase C and casein kinase II phosphorylation sites. The PEST scores cited supra are among the best ever reported in the literature.

[0073] pET32a-HRt is also an inducible E. coli expression plasmid. Protein expression is studied using the standard protocol for E. coli expression as also provided by the supplier. SDS-PAGE (10-20%) analysis of total protein isolated from quadruplicate E. coli BL21(DE3)/pET32a-HRt clones induced for protein expression reveals a high level of expression of protein product of the expected size for a HRt fusion protein just after 2 h of induction. Control strain E. coli BL21(DE3)/pET32a does not show induction of any protein expression at the high molecular weight region as compared to the E. coli BL21(DE3)/pET32a-HRt clones. This study confirms expression of protein product from the HRt insert. The protein product is not recoverable under non-denaturing conditions.

[0074] Cloning of HRt into GAL4 binding domain (BD) yeast two-hybrid (Y2H) vector: The HRt insert from pET32a-HRt is excised as an Eco RI-Xho I fragment (there is a unique Xho I site just adjacent to HRt insert) and inserted at the Eco RI-Sal I sites of Y2H-BD vector pGBKT7 (Catalog No. K1612-B; a component of Matchmaker two-hybrid System 3 (Catalog No. K1612-1) BD Biosciences Clontech, Palo Alto, Calif.) to obtain pGBKT7-HRt in which HRt is fused in-frame to GAL 4 DNA BD (this plasmid is also designated BD-HRt).

[0075] Pretransformed human brain MATCHMAKER cDNA Library Screen for HRt interaction partners: Pretransformed human brain MATCHMAKER high-complexity GAL4 cDNA library that has already been amplified and introduced into yeast strain Y187 (MATα) is used to screen for HRt interacting proteins. The yeast mating partner strain PJ69-2A (MATa), provided with the pretransformed library, contains two nutritional reporter genes (ADE2 and HIS3) under the control of different promoters that significantly reduce the incidence of false positives. The library host strain Y187 provides a third reporter gene (lacZ) for optional quantification of signal strength. The protocol as described in Clontech user manual (PT3183-1) is used. Briefly, the library is mixed with PJ69-2A strain that has been transformed with the BD-HRt plasmid in YPD medium containing adenine hemisulfate (0.004%) and kanamycin (0.005%) and incubated for 20-24 h at 30° C. The next day, the mating mixture is plated on Leu, Trp, His TDO that selects for two-hybrid interactions, and then the positive clones are screened for growth on Leu, Trp, His, Ade QDO, which is a more stringent condition for interaction. Colonies that grew well on QDO are also screened for lacZ expression by streaking on QDO-Xgal plates. Based on a visual assessment of colonies for the intensity of blue color, the clones are classified into high (H), medium (M), low (L) or very low (VL) categories.

[0076] Mating efficiency is calculated to be ˜8% (by plating dilutions on leucine and tryptophan double drop out DDO plate). Nearly 4 million cells representing ˜300,000 mated cells are plated on histidine selection plate (leucine, tryptophan and histidine triple drop out, TDO plate). A total of 232 His+ colonies are obtained of which 126 colonies also grew in the absence of adenine (adenine, histidine, leucine and tryptophan quadruple drop out, QDO plate) and turned blue on QDO-Xgal plates. Based on the rate and intensity of blue color-16 are high blue, 43 are medium blue, 33 are low blue and rest is very low blue.

[0077] The positive clones are expected to contain an AD-IP (interacting partner) that interacts with BD-HRt. To characterize IP, the sequence of IP is determined and matched to the human genome database. For this purpose, total DNA is isolated from the positive clones and PCR amplified with MATCHMAKER AD LD (long distance)-insert screening amplimers (Catalog No.9103-1; BD Biosciences Clontech, PaloAlto, Calif.). Reaction is conducted in 50 μl volume for 35 cycles using the conditions recommended with the Advantage2 PCR kit (Catalog No. K1910-1; BD Biosciences Clontech, PaloAlto, Calif.). The PCR product is sequenced using the sequencing primer: 5′ CTATTCGATGATGAAGATACCCCACCAAACCCA (SEQ ID NO:104) (catalog No. 9103-1; BD Biosciences Clontech, PaloAlto, Calif.). DNA sequence analysis and data base search for homology are performed using SeqWeb version 1.2 (in conjunction with Wisconsin Package Version 10.1).

[0078] Several human interacting partners that interact with HRt are identified as listed in Table 1. Proteins having SEQ ID NO: 8, SEQ ID NO: 13, SEQ ID NO: 25, SEQ ID NO: 35, SEQ ID NO: 43, SEQ ID NO: 65, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 79, SEQ ID NO: 83 appear to be new proteins. TABLE 1 Summary of BD-HRt(mouse) interaction with human brain c-DNA library in AD-Vector SEQ ID NO: GenBank Acc # Clone Identity # of hits XGAL DNA ORF E11456 Human ubiquitous receptor UR 3 + 1 H/M  1  2 V00594 Human metallothionein from cadmium-treated cells 2 H  3  4 AF055066 Human MHC class I region 1 H 11, 99 AL031676 Human sequence from clone RP4-753, 1 H 12 13 chromosome 21q M86511 Human monocyte antigen CD14 1 H 14 15 M60255 Human Sphingolipid activator protein 3 M 16 17 BC002902 Human synuclein-beta 1 M 18 19 X81625 Human C11 protein 1 M 20 21 BC002737 Human vesicle-associated membrane protein 2 1 M 22 23 AK026339 Human small intestine cDNA to mRNA clone HSI10987 1 M 24 25 M11560 Human aldolase A 3 M 26 27 AF151864 Human CGI-106 protein 1 M 28 29 AF220191 Human hypothalamus protein HSMNP1 3 M 30 31 M14328 Human alpha enolase 2 M 32 33 BC006358 Human hypothetical protein 3 M 34 35 U10099 Human POM-ZP3 1 M 36 37 AF159164 Human ankyrin repeat containing protein ASB-2 1 M 38 39 J02888 Human quinone oxidoreductase(NQO2) 1 M 40 41 D43951 Human pumilio(PUMH1) 1 M 44 45 U87309 Human VPS41 1 M 46 47 AB014514 Human KIAA0614 protein 1 M 48 49 AF141348 Human alpha-tubulin 1 L 50 U14603 Human tyrosine phosphatase type 1VA, member 2 1 L 51 52 BC005003 Human transcription factor Y, gamma 1 L 53 54 U02020 Human pre-B cell colony enhancing factor (PBEF) 1 L 55 AF016004 Human neuronal membrane glycoprotein M6b1 1 L 56 U48437 Human amyloid precursor like protein 1 L 57 58 L10911 Human splicing factor (CC1.4) 1 + 1 L/VL 59 60 AK024500 Human FLJ00109 protein 1 L 61 E11295 Human P31 1 L 62 U35376 Human repressor transcription factor ZNF85 1 L 63 AL096810 Human genomic region containing hypervariable mini 1 L 64 65 satellites Chromosome 10[10q26.3] AF261093 Human Thy-1 glycoprotein 1 L 66 67 AK023181 Human cDNA: FLJ21955 fis, clone FLJ13119 fis 1 L 68 AB001899 Human PACE4 (SPC4) 1 L 69 AR075562 Human ubiquitin 1 + 1 L/VL 70 71 BC009472 Human cDNA FLJ20109 fis clone COL05067 1 L 72 73 AK000463 Human cDNA FLJ20456 fis clone KAT05827 1 + 2 L/VL 74 75 AC005325 Human Chromosome17, clone hRPK60 1 L 76 U46005 Human MDC15 1 L 77 AK026840 Human cDNA: FLJ23187 fis, clone: LNG11989 1 L 78 79 U60337 Human □-mannosidase 1 L 80 81 AL031847 Human DNA sequence from clone RP1-120G22 on 1 L 82 83 chromosome 1p36.21-36.33 (Unknown) AB007896 Human KIAA0436 1 L 84 85 AY007158 Human clone CDABP0113 1 VL 86 87 AC007731 Human chromosome 22q11 clone b562f10 1 L 88 G29373 Human STS SHGC-32359 sequence tagged site 1 VL 89 AL050038 Human mRNA; cDNA DKFZp566J0124 1 H 90 X93334 Human mitochondrial cytochrome oxidase III 1 VL 91 Homology in a 3′-untranslated region M34641 HUMFGF1A Human fibroblast growth factor (FGF) 1 VL 92 receptor-1 mRNA AJ300461 Human mRNA for C11ORF25 gene 2 VL 94 X83543 Human APXL mRNA 1 M 95 X80818 Human mRNA for metabotropic glutamate receptor type 4 1 VL 96 Homology to RNA AF347015 Human mitochondrial gene for 16S rRNA 10 + 8 M/L-VL 98

EXAMPLE 2 Screen for Compounds That Disrupt BD-HRt><AD-IP Interaction

[0079] BD-HRt><AD-IP in yeast strain. AH 109 was used for compound screening. AH109 (a component of the Matchmaker two-hybrid System 3 (Catalog No. K1612-1) BD Biosciences Clontech, Palo Alto, Calif.) is a desirable yeast reporter strain for Y2H interaction. It contains ADE2, HIS3, lacZ and MEL1 reporter genes, each of which uses a distinct GAL4-responsive promoter. The various Y2H recombinant plasmids are introduced into the yeast strain AH109 by using a lithium acetate-mediated yeast transformation protocol as provided by the supplier of the Y2H system (BD Biosciences Clontech, PaloAlto, Calif.). Transformants for combined AD and BD plasmids are selected based on their ability to grow in Leu and Trp double drop out medium (DDO).

[0080] Interaction between AD and BD fusion proteins (Y2H interaction) will bring the AD and BD domains of GAL 4 protein close to each other and thus reconstitute a functional GAL 4 protein. This will allow transformants to grow on Leu, Trp, His, Ade quadruple drop out medium (QDO). Growth rate on QDO, as well as a measure of MEL1 (alpha-galactosidase) or lacZ (beta-galactosidase) activities will give a more or less quantitative measure of avidity of Y2H interaction.

[0081] Growth inhibition of AH109 (BD-HRt><AD-IP) strain in Leu, Trp, His, Ade QDO, but not on Leu, Trp DDO is used as an initial screen for compounds for disruption of HRt-IP interaction. A diverse library of compounds is screened. Microtiter plates with 200 μl of QDO and DDO media seeded with freshly cultured yeast cells at 0.01-0.03 optical density at 600 nm (OD600) are treated with various test compounds. Stock solutions of test compounds at 20 mM are made in DMSO and tested at 400 μM final concentration. The plates are incubated without shaking at 25° C. OD600 is first measured after addition of compounds and recorded for the next 8-10 days. Wells with no compound added (positive control) are expected to reach saturation growth (˜0.7 within 3 days of incubation). Wells with only media and no cells inoculated are expected to remain at the initial OD600 value (˜0.03) over the entire period of the assay. Positive compounds from this assay are tested against an unrelated Y2H interaction (p53><T antigen) assay. pGBKT7-53 and pGADT7-T plasmids were used to establish an unrelated (to HRt) Y2H interaction in which p53 protein interacts with T antigen. These plasmids are part of the Matchmaker two-Hybrid system 3(catalog # K1612-1, BD Biosciences Clontech, Palo Alto, Calif.).

EXAMPLE 3 Screen for Compounds That Enhance BD-HRt><AD-IP Interaction

[0082] Increase in alpha-galactosidase activity of AH109 (BD-HRt><AD-IP) strain grown in Leu, Trp, His, Ade QDO in the presence of various test compounds is used to screen for agonists of BD-HRt><AD-IP interaction. A diverse library of compounds is screened. Microtiter plates with 200 μl of QDO media seeded with freshly cultured yeast cells at 0.05 optical density at 600 nm (OD600) are treated with various test compounds. Stock solutions of test compounds at 20 mM are made in DMSO and tested at 400 μM final concentration. The plates are incubated for 34 days without shaking at 25° C. Plates are briefly agitated to obtain uniform suspension of cells and OD600 measured. Cells are pelleted and an aliquot of medium is assayed for alpha-galactosidase activity by incubating for 10-60 minutes at 30 degree Centigrade with orthonitrophenyl alpha-D-galactoside substrate in a final volume of 100 μl. This substrate is hydrolyzed by the enzyme to ortho-nitro phenol (yellow colored product) and galactose. The reaction is terminated with 100 μl of 1M sodium carbonate solution when sufficient yellow color has developed. The amount of ortho-nitro phenol generated is determined by measuring OD at 420 nm. The alpha-galactosidase enzyme activity units is expressed as: 1000×OD 420/t×OD 600 (where t refers to elapsed incubation time in minutes). Positive compounds from this assay are tested against an unrelated Y2H interaction (p53><T antigen) assay to ensure that the compounds are specific to BD-HRt><AD-IP interaction.

EXAMPLE 4 Animal Model for Hair Growth Retardation (HGR) Activity

[0083] Male C3H mice (˜42-48 days old and weighing ˜24 g) purchased from Harlan are acclimatized for 2 days and ˜2 cm² area on their back is shaved closely with an electric hair trimmer. To the shaved area, −300 μl of Nair lotion (NEW! Quick'n Easy 4 Minute Formula) is thinly smeared with a gloved fingertip for ˜30 sec. The area is wiped with Kimwipes for ˜15 sec and immediately washed under a gentle stream of lukewarm water for ˜50 sec and patted dry with Kimwipes. Test materials are applied (5 animals/test material) daily for 17 days. The shaved area is visually observed every day for anagen conversion and hair growth. Animal backs are photographed on day 17. In this model Dolgel Gel (5% ibuprofen) has clear HGR activity (100% HGR activity), as evidenced by absence of any hair or pigmentation at day 17. Control treatment (60% ethanol, 20% propylene glycol and 20% Transcutol) shows clear hair growth (0% HGR activity) and show nearly 100% anagen conversion within 12 days. Test materials are compared to such controls to determine efficacy at HGR.

EXAMPLE 5 Animal Model for Hair Growth Stimulation (HGS) Activity

[0084] Male C3H mice (˜42-48 days old and weighing ˜24 g) purchased from Harlan are acclimatized for 2 days and ˜2 cm² area on their back is shaved closely with an electric hair trimmer. To the shaved area, ˜300 μl of Nair lotion (NEW! Quick'n Easy 4 Minute Formula) is thinly smeared with a gloved fingertip for ˜30 sec. The area is wiped with Kimwipes for ˜15 sec and immediately washed under a gentle stream of lukewarm water for ˜50 sec and patted dry with Kimwipes. Test materials are applied (5 animals/test material) daily for 17 days. The shaved area is visually observed every day for anagen conversion and hair growth. Animal backs are photographed on day 8 and 17. In this model Triiodo thyronine (T3) has clear HGS activity (100% HGS activity), as evidenced by early onset of pigmentation and clear increase in hair length at day 17 compared to control treatment (60% ethanol, 20% propylene glycol and 20% Transcutol).

[0085] All documents cited in the Detailed Description of the Invention are, in relevant part, incorporated herein by reference; the citation of any document is not to be construed as an admission that it is prior art with respect to the present invention. While particular embodiments of the present invention have been illustrated and d, it would be obvious to those skilled in the art that various other changes and ations can be made without departing from the spirit and scope of the invention. It is e intended to cover in the appended claims all such changes and modifications that are the scope of this invention.

1 94 1 705 DNA Homo sapiens CDS (21)..(704) 1 gaattcgcgg ccgcgtcgac cgt gac ccc acc atg tcc tct cct acc acg agt 53 Arg Asp Pro Thr Met Ser Ser Pro Thr Thr Ser 1 5 10 tcc ctg gat acc ccc ctg cct gga aat ggc ccc cct cag cct ggc gcc 101 Ser Leu Asp Thr Pro Leu Pro Gly Asn Gly Pro Pro Gln Pro Gly Ala 15 20 25 cct tct tct tca ccc act gta aag gag gag ggt ccg gag ccg tgg ccc 149 Pro Ser Ser Ser Pro Thr Val Lys Glu Glu Gly Pro Glu Pro Trp Pro 30 35 40 ggg ggt ccg gac cct gat gtc cca ggc act gat gag gcc agc tca gcc 197 Gly Gly Pro Asp Pro Asp Val Pro Gly Thr Asp Glu Ala Ser Ser Ala 45 50 55 tgc agc aca gac tgg gtc atc cca gat ccc gaa gag gaa cca gag cgc 245 Cys Ser Thr Asp Trp Val Ile Pro Asp Pro Glu Glu Glu Pro Glu Arg 60 65 70 75 aag cga aag aag ggc cca gcc ccg aag atg ctg ggc cac gag ctt tgc 293 Lys Arg Lys Lys Gly Pro Ala Pro Lys Met Leu Gly His Glu Leu Cys 80 85 90 cgt gtc tgt ggg gac aag gcc tcc ggc ttc cac tac aac gtg ctc agc 341 Arg Val Cys Gly Asp Lys Ala Ser Gly Phe His Tyr Asn Val Leu Ser 95 100 105 tgc gaa ggc tgc aag ggc ttc ttc cgg cgc agt gtg gtc cgt ggt ggg 389 Cys Glu Gly Cys Lys Gly Phe Phe Arg Arg Ser Val Val Arg Gly Gly 110 115 120 gcc agg cgc tat gcc tgc cgg ggt ggc gga acc tgc cag atg gac gct 437 Ala Arg Arg Tyr Ala Cys Arg Gly Gly Gly Thr Cys Gln Met Asp Ala 125 130 135 ttc atg cgg cgc aag tgc cag cag tgc cgg ctg cgc aag tgc aag gag 485 Phe Met Arg Arg Lys Cys Gln Gln Cys Arg Leu Arg Lys Cys Lys Glu 140 145 150 155 gca ggg atg agg gag cag tgc gtc ctt tct gaa gaa cag atc cgg aag 533 Ala Gly Met Arg Glu Gln Cys Val Leu Ser Glu Glu Gln Ile Arg Lys 160 165 170 aag aag att cgg aaa cag cag cag cag gag tca cag tca cag tcg cag 581 Lys Lys Ile Arg Lys Gln Gln Gln Gln Glu Ser Gln Ser Gln Ser Gln 175 180 185 tca cct gtg ggg ccg cag ggc agc agc agc tca gcc tct ggg cct ggg 629 Ser Pro Val Gly Pro Gln Gly Ser Ser Ser Ser Ala Ser Gly Pro Gly 190 195 200 gct tnc cct ggt gga tct gan gca ggc agc cag ggc tcc ggg gga agg 677 Ala Xaa Pro Gly Gly Ser Xaa Ala Gly Ser Gln Gly Ser Gly Gly Arg 205 210 215 cga ggg tgt cca gct aac agc ggc tca a 705 Arg Gly Cys Pro Ala Asn Ser Gly Ser 220 225 2 228 PRT Homo sapiens misc_feature (205)..(205) The ′Xaa′ at location 205 stands for Tyr, Cys, Ser, or Phe. 2 Arg Asp Pro Thr Met Ser Ser Pro Thr Thr Ser Ser Leu Asp Thr Pro 1 5 10 15 Leu Pro Gly Asn Gly Pro Pro Gln Pro Gly Ala Pro Ser Ser Ser Pro 20 25 30 Thr Val Lys Glu Glu Gly Pro Glu Pro Trp Pro Gly Gly Pro Asp Pro 35 40 45 Asp Val Pro Gly Thr Asp Glu Ala Ser Ser Ala Cys Ser Thr Asp Trp 50 55 60 Val Ile Pro Asp Pro Glu Glu Glu Pro Glu Arg Lys Arg Lys Lys Gly 65 70 75 80 Pro Ala Pro Lys Met Leu Gly His Glu Leu Cys Arg Val Cys Gly Asp 85 90 95 Lys Ala Ser Gly Phe His Tyr Asn Val Leu Ser Cys Glu Gly Cys Lys 100 105 110 Gly Phe Phe Arg Arg Ser Val Val Arg Gly Gly Ala Arg Arg Tyr Ala 115 120 125 Cys Arg Gly Gly Gly Thr Cys Gln Met Asp Ala Phe Met Arg Arg Lys 130 135 140 Cys Gln Gln Cys Arg Leu Arg Lys Cys Lys Glu Ala Gly Met Arg Glu 145 150 155 160 Gln Cys Val Leu Ser Glu Glu Gln Ile Arg Lys Lys Lys Ile Arg Lys 165 170 175 Gln Gln Gln Gln Glu Ser Gln Ser Gln Ser Gln Ser Pro Val Gly Pro 180 185 190 Gln Gly Ser Ser Ser Ser Ala Ser Gly Pro Gly Ala Xaa Pro Gly Gly 195 200 205 Ser Xaa Ala Gly Ser Gln Gly Ser Gly Gly Arg Arg Gly Cys Pro Ala 210 215 220 Asn Ser Gly Ser 225 3 386 DNA Homo sapiens CDS (36)..(386) 3 gaattcgcgg ccgcgtcgac gtcgacgcgg ccgcg gtc cca gcg aac ccg cgt 53 Val Pro Ala Asn Pro Arg 1 5 gca acc tgt ccc gac tct agc cgc ctc ttc agc tcg cca tgg atc cca 101 Ala Thr Cys Pro Asp Ser Ser Arg Leu Phe Ser Ser Pro Trp Ile Pro 10 15 20 act gct cct gcg ccg ccg gtg act cct gca cct gcg ccg gct cct gca 149 Thr Ala Pro Ala Pro Pro Val Thr Pro Ala Pro Ala Pro Ala Pro Ala 25 30 35 aat gca aag agt gca aat gca cct cct gca aga aaa gct gct gct cct 197 Asn Ala Lys Ser Ala Asn Ala Pro Pro Ala Arg Lys Ala Ala Ala Pro 40 45 50 gct gcc ctg tgg gct gtg cca agt gtg ccc agg gct gca tct gca aag 245 Ala Ala Leu Trp Ala Val Pro Ser Val Pro Arg Ala Ala Ser Ala Lys 55 60 65 70 ggg cgt cgg aca agt gca gct gct gcg cct gat gct ggg aca gcc ccg 293 Gly Arg Arg Thr Ser Ala Ala Ala Ala Pro Asp Ala Gly Thr Ala Pro 75 80 85 ctc cca gat gta aag aac gcg act tcc aca aac ctg gat ttt tta tgt 341 Leu Pro Asp Val Lys Asn Ala Thr Ser Thr Asn Leu Asp Phe Leu Cys 90 95 100 aca acc ctg acc gtg acc gtt tgc tat att cct ttt tct atg aaa 386 Thr Thr Leu Thr Val Thr Val Cys Tyr Ile Pro Phe Ser Met Lys 105 110 115 4 117 PRT Homo sapiens 4 Val Pro Ala Asn Pro Arg Ala Thr Cys Pro Asp Ser Ser Arg Leu Phe 1 5 10 15 Ser Ser Pro Trp Ile Pro Thr Ala Pro Ala Pro Pro Val Thr Pro Ala 20 25 30 Pro Ala Pro Ala Pro Ala Asn Ala Lys Ser Ala Asn Ala Pro Pro Ala 35 40 45 Arg Lys Ala Ala Ala Pro Ala Ala Leu Trp Ala Val Pro Ser Val Pro 50 55 60 Arg Ala Ala Ser Ala Lys Gly Arg Arg Thr Ser Ala Ala Ala Ala Pro 65 70 75 80 Asp Ala Gly Thr Ala Pro Leu Pro Asp Val Lys Asn Ala Thr Ser Thr 85 90 95 Asn Leu Asp Phe Leu Cys Thr Thr Leu Thr Val Thr Val Cys Tyr Ile 100 105 110 Pro Phe Ser Met Lys 115 5 443 DNA Homo sapiens misc_feature (13)..(413) n represents a, c, t or g 5 tggaacagtg ganganagct ttgtatatnt atntatnnat ntatntatnt atntatntat 60 ntaaactnna taggagnacn tagaggagtg cctaatanat ntanngcncg annccanata 120 cntgntanat nngagncagc ncttttntgg gggncatcta ttaacaagag tgtaaantan 180 attannnacn tgtnntataa tcagcanaga ttnatcnntn acacgcaaan ngcncttang 240 ggagtannca nacaactaag tgccnctanc taantggcnt gngaaaacag anncacnctg 300 nacataatat tancagagag gggngatata tgngatatgc ngggnggaaa ntgngacnct 360 tcnattcaca acagtgntgc cccaantgga accatnatag ggggnnggnn ggnactaaca 420 tctctagtca gcgagctggc aga 443 6 106 DNA Homo sapiens CDS (24)..(104) 6 gaattcgcgg ccgcgtcgac ggg ggt tgc agt gag ccg aga tcg tgc cac tgt 53 Gly Cys Ser Glu Pro Arg Ser Cys His Cys 1 5 10 act cca gcc tgg gca aca gag caa gac tcc atc tca gcc aaa aat aat 101 Thr Pro Ala Trp Ala Thr Glu Gln Asp Ser Ile Ser Ala Lys Asn Asn 15 20 25 aat aa 106 Asn 7 27 PRT Homo sapiens 7 Gly Cys Ser Glu Pro Arg Ser Cys His Cys Thr Pro Ala Trp Ala Thr 1 5 10 15 Glu Gln Asp Ser Ile Ser Ala Lys Asn Asn Asn 20 25 8 401 DNA Homo sapiens CDS (126)..(401) 8 gaattcgcgg ccgcgtcgac gatcagggtt cacagaggag ggaactgaat gacatcccag 60 gattacataa actgtcagag gcagccgaag agttcacaag tgtgaagcct ggaagccggc 120 gggtg ccg ctg tgt agg aaa gaa gct aaa gca ctt cca gag cct gtc cgg 170 Pro Leu Cys Arg Lys Glu Ala Lys Ala Leu Pro Glu Pro Val Arg 1 5 10 15 agc tca gag gtt cgg aag act tat cga cca tgg agc gcg cgt cct gct 218 Ser Ser Glu Val Arg Lys Thr Tyr Arg Pro Trp Ser Ala Arg Pro Ala 20 25 30 tgt tgc tgc tgc tgc tgc cgc tgg tgc acg tct ctg cga cca cgc cag 266 Cys Cys Cys Cys Cys Cys Arg Trp Cys Thr Ser Leu Arg Pro Arg Gln 35 40 45 aac ctt gtg agc tgg acg atg aag att tcc gct gcg tct gca act tct 314 Asn Leu Val Ser Trp Thr Met Lys Ile Ser Ala Ala Ser Ala Thr Ser 50 55 60 ccg aac ctc agc ccg act ggt ccc gaa gcc ttc cag tgt gtg tct gca 362 Pro Asn Leu Ser Pro Thr Gly Pro Glu Ala Phe Gln Cys Val Ser Ala 65 70 75 gta aga agg tgg gag aat cca tgc cgg cgg tct tca acc 401 Val Arg Arg Trp Glu Asn Pro Cys Arg Arg Ser Ser Thr 80 85 90 9 92 PRT Homo sapiens 9 Pro Leu Cys Arg Lys Glu Ala Lys Ala Leu Pro Glu Pro Val Arg Ser 1 5 10 15 Ser Glu Val Arg Lys Thr Tyr Arg Pro Trp Ser Ala Arg Pro Ala Cys 20 25 30 Cys Cys Cys Cys Cys Arg Trp Cys Thr Ser Leu Arg Pro Arg Gln Asn 35 40 45 Leu Val Ser Trp Thr Met Lys Ile Ser Ala Ala Ser Ala Thr Ser Pro 50 55 60 Asn Leu Ser Pro Thr Gly Pro Glu Ala Phe Gln Cys Val Ser Ala Val 65 70 75 80 Arg Arg Trp Glu Asn Pro Cys Arg Arg Ser Ser Thr 85 90 10 710 DNA Homo sapiens CDS (30)..(710) 10 gaattcgcgg ccgcgtcgac ctggagtcc aat aag atc cca gag ctg gac atg 53 Asn Lys Ile Pro Glu Leu Asp Met 1 5 act gag gtg gtg gcc ccc ttc atg gcc aac atc cct ctc ctc ctc tac 101 Thr Glu Val Val Ala Pro Phe Met Ala Asn Ile Pro Leu Leu Leu Tyr 10 15 20 cct cag gac ggc ccc cgc agc aag ccc cag cca aag gat aat ggg gac 149 Pro Gln Asp Gly Pro Arg Ser Lys Pro Gln Pro Lys Asp Asn Gly Asp 25 30 35 40 gtt tgc cag gac tgc att cag atg gtg act gac atc cag act gct gta 197 Val Cys Gln Asp Cys Ile Gln Met Val Thr Asp Ile Gln Thr Ala Val 45 50 55 cgg acc aac tcc acc ttt gtc cag gcc ttg gtg gaa cat gtc aag gag 245 Arg Thr Asn Ser Thr Phe Val Gln Ala Leu Val Glu His Val Lys Glu 60 65 70 gag tgt gac cgc ctg ggc cct ggc atg gcc gac ata tgc aag aac tat 293 Glu Cys Asp Arg Leu Gly Pro Gly Met Ala Asp Ile Cys Lys Asn Tyr 75 80 85 atc agc cag tat tct gaa att gct atc cag atg atg atg cac atg cag 341 Ile Ser Gln Tyr Ser Glu Ile Ala Ile Gln Met Met Met His Met Gln 90 95 100 gat cag caa ccc aag gag atc tgt gcg ctg gtt ggg ttc tgt gat gag 389 Asp Gln Gln Pro Lys Glu Ile Cys Ala Leu Val Gly Phe Cys Asp Glu 105 110 115 120 gtg aaa gag atg ccc atg cag act ctg gtc ccc gcc aaa gtg gcc tcc 437 Val Lys Glu Met Pro Met Gln Thr Leu Val Pro Ala Lys Val Ala Ser 125 130 135 aag aat gtc atc cct gcc ctg gaa ctg gtg gag ccc att aag aag cac 485 Lys Asn Val Ile Pro Ala Leu Glu Leu Val Glu Pro Ile Lys Lys His 140 145 150 gag gtc cca gca aag tct gat gtt tac tgt gag gtg tgt gaa ttc ctg 533 Glu Val Pro Ala Lys Ser Asp Val Tyr Cys Glu Val Cys Glu Phe Leu 155 160 165 gtg aag gag gtg acc aag ctg att gac aac aac aag act gag aaa gaa 581 Val Lys Glu Val Thr Lys Leu Ile Asp Asn Asn Lys Thr Glu Lys Glu 170 175 180 ata ctc gac gct ttt gac aaa atg tgc tcg aag ctg ccg aag tcc ctg 629 Ile Leu Asp Ala Phe Asp Lys Met Cys Ser Lys Leu Pro Lys Ser Leu 185 190 195 200 tcg gaa gag tgc cag gag gtg gtg gac acg tac ggc agc tcc atc ctg 677 Ser Glu Glu Cys Gln Glu Val Val Asp Thr Tyr Gly Ser Ser Ile Leu 205 210 215 tcc atc ctg ctg gag gag gtc agc cct gag ctg 710 Ser Ile Leu Leu Glu Glu Val Ser Pro Glu Leu 220 225 11 227 PRT Homo sapiens 11 Asn Lys Ile Pro Glu Leu Asp Met Thr Glu Val Val Ala Pro Phe Met 1 5 10 15 Ala Asn Ile Pro Leu Leu Leu Tyr Pro Gln Asp Gly Pro Arg Ser Lys 20 25 30 Pro Gln Pro Lys Asp Asn Gly Asp Val Cys Gln Asp Cys Ile Gln Met 35 40 45 Val Thr Asp Ile Gln Thr Ala Val Arg Thr Asn Ser Thr Phe Val Gln 50 55 60 Ala Leu Val Glu His Val Lys Glu Glu Cys Asp Arg Leu Gly Pro Gly 65 70 75 80 Met Ala Asp Ile Cys Lys Asn Tyr Ile Ser Gln Tyr Ser Glu Ile Ala 85 90 95 Ile Gln Met Met Met His Met Gln Asp Gln Gln Pro Lys Glu Ile Cys 100 105 110 Ala Leu Val Gly Phe Cys Asp Glu Val Lys Glu Met Pro Met Gln Thr 115 120 125 Leu Val Pro Ala Lys Val Ala Ser Lys Asn Val Ile Pro Ala Leu Glu 130 135 140 Leu Val Glu Pro Ile Lys Lys His Glu Val Pro Ala Lys Ser Asp Val 145 150 155 160 Tyr Cys Glu Val Cys Glu Phe Leu Val Lys Glu Val Thr Lys Leu Ile 165 170 175 Asp Asn Asn Lys Thr Glu Lys Glu Ile Leu Asp Ala Phe Asp Lys Met 180 185 190 Cys Ser Lys Leu Pro Lys Ser Leu Ser Glu Glu Cys Gln Glu Val Val 195 200 205 Asp Thr Tyr Gly Ser Ser Ile Leu Ser Ile Leu Leu Glu Glu Val Ser 210 215 220 Pro Glu Leu 225 12 320 DNA Homo sapiens CDS (21)..(320) 12 gaattcgcgg ccgcgtcgac acg aga tct tcc ttc cgc tct gag gca acc ccc 53 Thr Arg Ser Ser Phe Arg Ser Glu Ala Thr Pro 1 5 10 tcg gag cct gtg tta gtg tct gtc cat ctg tct gtc cta ccc gcc cgc 101 Ser Glu Pro Val Leu Val Ser Val His Leu Ser Val Leu Pro Ala Arg 15 20 25 gtc caa ccc cgg ggc atg gac agg gcc agg gtt gcg gtc gcg gct ggg 149 Val Gln Pro Arg Gly Met Asp Arg Ala Arg Val Ala Val Ala Ala Gly 30 35 40 agc ctc gcc cct cca gtg ttg cct cct ccc atc cag cgt ctg cgc gga 197 Ser Leu Ala Pro Pro Val Leu Pro Pro Pro Ile Gln Arg Leu Arg Gly 45 50 55 tgt agc atg ttc tat gtg ttt tta aac gaa gat ccg agc gac ggc tcc 245 Cys Ser Met Phe Tyr Val Phe Leu Asn Glu Asp Pro Ser Asp Gly Ser 60 65 70 75 tcc ccg atc ccc gac agt ggc tct cca agc ggc ccc cgg gca gcc cca 293 Ser Pro Ile Pro Asp Ser Gly Ser Pro Ser Gly Pro Arg Ala Ala Pro 80 85 90 gag cac ccc gcc cga ctc cca tta acc 320 Glu His Pro Ala Arg Leu Pro Leu Thr 95 100 13 100 PRT Homo sapiens 13 Thr Arg Ser Ser Phe Arg Ser Glu Ala Thr Pro Ser Glu Pro Val Leu 1 5 10 15 Val Ser Val His Leu Ser Val Leu Pro Ala Arg Val Gln Pro Arg Gly 20 25 30 Met Asp Arg Ala Arg Val Ala Val Ala Ala Gly Ser Leu Ala Pro Pro 35 40 45 Val Leu Pro Pro Pro Ile Gln Arg Leu Arg Gly Cys Ser Met Phe Tyr 50 55 60 Val Phe Leu Asn Glu Asp Pro Ser Asp Gly Ser Ser Pro Ile Pro Asp 65 70 75 80 Ser Gly Ser Pro Ser Gly Pro Arg Ala Ala Pro Glu His Pro Ala Arg 85 90 95 Leu Pro Leu Thr 100 14 281 DNA Homo sapiens CDS (21)..(281) 14 gaattcgcgg ccgcgtcgac aaa agg ata aat ctc att tca cag aca aag aga 53 Lys Arg Ile Asn Leu Ile Ser Gln Thr Lys Arg 1 5 10 ccg gac agg aac atg agc tta tcg aga gca tgc ccc tgt tgg aat ggt 101 Pro Asp Arg Asn Met Ser Leu Ser Arg Ala Cys Pro Cys Trp Asn Gly 15 20 25 ttg cta aca act ata aaa aat ttg gag cta ctg ttg gaa att gtc aca 149 Leu Leu Thr Thr Ile Lys Asn Leu Glu Leu Leu Leu Glu Ile Val Thr 30 35 40 gat aaa tca caa gaa ggg tct cag ttt gtg aaa gga ttt ggt gga att 197 Asp Lys Ser Gln Glu Gly Ser Gln Phe Val Lys Gly Phe Gly Gly Ile 45 50 55 gga ggt atc ttg cgg tac cga gta gat ttc cag gga atg gaa tac caa 245 Gly Gly Ile Leu Arg Tyr Arg Val Asp Phe Gln Gly Met Glu Tyr Gln 60 65 70 75 gga gga gac gat gaa ttt ttt gac ctt gat gac tac 281 Gly Gly Asp Asp Glu Phe Phe Asp Leu Asp Asp Tyr 80 85 15 87 PRT Homo sapiens 15 Lys Arg Ile Asn Leu Ile Ser Gln Thr Lys Arg Pro Asp Arg Asn Met 1 5 10 15 Ser Leu Ser Arg Ala Cys Pro Cys Trp Asn Gly Leu Leu Thr Thr Ile 20 25 30 Lys Asn Leu Glu Leu Leu Leu Glu Ile Val Thr Asp Lys Ser Gln Glu 35 40 45 Gly Ser Gln Phe Val Lys Gly Phe Gly Gly Ile Gly Gly Ile Leu Arg 50 55 60 Tyr Arg Val Asp Phe Gln Gly Met Glu Tyr Gln Gly Gly Asp Asp Glu 65 70 75 80 Phe Phe Asp Leu Asp Asp Tyr 85 16 170 DNA Homo sapiens CDS (21)..(170) 16 gaattcgcgg ccgcgtcgac ccg ctg ccc ccg cca tgt ctg cta ccg ctg cca 53 Pro Leu Pro Pro Pro Cys Leu Leu Pro Leu Pro 1 5 10 cgg ccc ccc ctg ctg ccc cgg ctg ggg agg gtg gtc ccc ctg cac ccc 101 Arg Pro Pro Leu Leu Pro Arg Leu Gly Arg Val Val Pro Leu His Pro 15 20 25 ctc caa acc tca cca gta aca gga gac tgc agc aga ccc agg ccc agg 149 Leu Gln Thr Ser Pro Val Thr Gly Asp Cys Ser Arg Pro Arg Pro Arg 30 35 40 tgg atg agg tgg tgg aca tca 170 Trp Met Arg Trp Trp Thr Ser 45 50 17 50 PRT Homo sapiens 17 Pro Leu Pro Pro Pro Cys Leu Leu Pro Leu Pro Arg Pro Pro Leu Leu 1 5 10 15 Pro Arg Leu Gly Arg Val Val Pro Leu His Pro Leu Gln Thr Ser Pro 20 25 30 Val Thr Gly Asp Cys Ser Arg Pro Arg Pro Arg Trp Met Arg Trp Trp 35 40 45 Thr Ser 50 18 554 DNA Homo sapiens CDS (381)..(554) 18 naattcgcgg ccgcgtcgac gactccggct atgtcatcgc cctgcgcagc gtacatcact 60 gacaacatgc agnctcctca gcttccaccg tggggacctc atcaagctgc tgccggnggc 120 caccctggag ccaggctggc agtttggctc tgccgggggc cgttccggac tctttcctgc 180 cgacatagtg cagccggctg ccgctcccga cttttccttc tccaaggagc agaggagtgg 240 ctggcacaag ggtcagctgt ccaacgggga accagggctg gctcggtggg acagggcctc 300 agagcgccct gcccaccctt ggagccaggc acacagtgac gactcggagg ccaccagcct 360 gtcctctgtg gcctatgcct ttc tgc ccg act ccc aca gct aca cca tgc agg 413 Phe Cys Pro Thr Pro Thr Ala Thr Pro Cys Arg 1 5 10 aat tcg ccc ggc gtt act tcc gga ggt ccc agg cct tgc tgg gcc aga 461 Asn Ser Pro Gly Val Thr Ser Gly Gly Pro Arg Pro Cys Trp Ala Arg 15 20 25 ctg atg gag gtg ccg cag gaa agg aca cgg aca gcc tgg tgc agt aca 509 Leu Met Glu Val Pro Gln Glu Arg Thr Arg Thr Ala Trp Cys Ser Thr 30 35 40 cca agg ctc cca tcc agg agt cgc tcc tca gcc tca gtg atg atg 554 Pro Arg Leu Pro Ser Arg Ser Arg Ser Ser Ala Ser Val Met Met 45 50 55 19 58 PRT Homo sapiens 19 Phe Cys Pro Thr Pro Thr Ala Thr Pro Cys Arg Asn Ser Pro Gly Val 1 5 10 15 Thr Ser Gly Gly Pro Arg Pro Cys Trp Ala Arg Leu Met Glu Val Pro 20 25 30 Gln Glu Arg Thr Arg Thr Ala Trp Cys Ser Thr Pro Arg Leu Pro Ser 35 40 45 Arg Ser Arg Ser Ser Ala Ser Val Met Met 50 55 20 388 DNA Homo sapiens CDS (21)..(386) 20 gaattcgcgg ccgcgtcgac aat ggc gag act acc acc caa ggg ttg gat ggg 53 Asn Gly Glu Thr Thr Thr Gln Gly Leu Asp Gly 1 5 10 ctg tct gag cgc tgt gcc cag tac aag aag gac gga gct gac ttc gcc 101 Leu Ser Glu Arg Cys Ala Gln Tyr Lys Lys Asp Gly Ala Asp Phe Ala 15 20 25 aag tgg cgt tgt gtg ctg aag att ggg gaa cac acc ccc tca gcc ctc 149 Lys Trp Arg Cys Val Leu Lys Ile Gly Glu His Thr Pro Ser Ala Leu 30 35 40 gcc atc atg gaa aat gcc aat gtt ctg gcc cgt tat gcc agt atc tgc 197 Ala Ile Met Glu Asn Ala Asn Val Leu Ala Arg Tyr Ala Ser Ile Cys 45 50 55 cag cag aat ggc att gtg ccc atc gtg gag cct gag atc ctc cct gat 245 Gln Gln Asn Gly Ile Val Pro Ile Val Glu Pro Glu Ile Leu Pro Asp 60 65 70 75 ggg gac cat gac ttg aag cgc tgc cag tat gtg acc gag aag gtg ctg 293 Gly Asp His Asp Leu Lys Arg Cys Gln Tyr Val Thr Glu Lys Val Leu 80 85 90 gct gct gtc tac aag gct ctg agt gac cac cac atc tac ctg gaa ggc 341 Ala Ala Val Tyr Lys Ala Leu Ser Asp His His Ile Tyr Leu Glu Gly 95 100 105 ncc ttg ctg aag ccc aac atg gtc acc cca agc cat gct ttc act ca 388 Xaa Leu Leu Lys Pro Asn Met Val Thr Pro Ser His Ala Phe Thr 110 115 120 21 122 PRT Homo sapiens misc_feature (108)..(108) The ′Xaa′ at location 108 stands for Thr, Ala, Pro, or Ser. 21 Asn Gly Glu Thr Thr Thr Gln Gly Leu Asp Gly Leu Ser Glu Arg Cys 1 5 10 15 Ala Gln Tyr Lys Lys Asp Gly Ala Asp Phe Ala Lys Trp Arg Cys Val 20 25 30 Leu Lys Ile Gly Glu His Thr Pro Ser Ala Leu Ala Ile Met Glu Asn 35 40 45 Ala Asn Val Leu Ala Arg Tyr Ala Ser Ile Cys Gln Gln Asn Gly Ile 50 55 60 Val Pro Ile Val Glu Pro Glu Ile Leu Pro Asp Gly Asp His Asp Leu 65 70 75 80 Lys Arg Cys Gln Tyr Val Thr Glu Lys Val Leu Ala Ala Val Tyr Lys 85 90 95 Ala Leu Ser Asp His His Ile Tyr Leu Glu Gly Xaa Leu Leu Lys Pro 100 105 110 Asn Met Val Thr Pro Ser His Ala Phe Thr 115 120 22 284 DNA Homo sapiens CDS (21)..(284) 22 gaattcgcgg ccgcgtcgac caa gga gaa ggc aaa gga gac ggc act ggc agc 53 Gln Gly Glu Gly Lys Gly Asp Gly Thr Gly Ser 1 5 10 tac aga gaa ggc caa gga cct cgc cag caa ggc ggc cac caa gaa gca 101 Tyr Arg Glu Gly Gln Gly Pro Arg Gln Gln Gly Gly His Gln Glu Ala 15 20 25 gca gca gca gca aca gtt tgt gta gcc agt cta cca cca cca cag cac 149 Ala Ala Ala Ala Thr Val Cys Val Ala Ser Leu Pro Pro Pro Gln His 30 35 40 ccc aga cag cta ggc tta gcc cct ctg ccc tcc ctt cat tgt act tta 197 Pro Arg Gln Leu Gly Leu Ala Pro Leu Pro Ser Leu His Cys Thr Leu 45 50 55 tca tta aaa atc aac ttc cag ccc tgt ctg ctg tct acg tgg tgg gtt 245 Ser Leu Lys Ile Asn Phe Gln Pro Cys Leu Leu Ser Thr Trp Trp Val 60 65 70 75 gtg ggg atg cag ttt ggc atc tgc agt aca cca agc aca 284 Val Gly Met Gln Phe Gly Ile Cys Ser Thr Pro Ser Thr 80 85 23 88 PRT Homo sapiens 23 Gln Gly Glu Gly Lys Gly Asp Gly Thr Gly Ser Tyr Arg Glu Gly Gln 1 5 10 15 Gly Pro Arg Gln Gln Gly Gly His Gln Glu Ala Ala Ala Ala Ala Thr 20 25 30 Val Cys Val Ala Ser Leu Pro Pro Pro Gln His Pro Arg Gln Leu Gly 35 40 45 Leu Ala Pro Leu Pro Ser Leu His Cys Thr Leu Ser Leu Lys Ile Asn 50 55 60 Phe Gln Pro Cys Leu Leu Ser Thr Trp Trp Val Val Gly Met Gln Phe 65 70 75 80 Gly Ile Cys Ser Thr Pro Ser Thr 85 24 323 DNA Homo sapiens CDS (45)..(323) 24 gaattcgcgg ccgcgtcgac gaaagaggtc accaagggca gagg tgt cca ggc cgg 56 Cys Pro Gly Arg 1 agc cag ggg ccc cac tgt tgg gat gct ggc tgc agt ggg gcg ccc caa 104 Ser Gln Gly Pro His Cys Trp Asp Ala Gly Cys Ser Gly Ala Pro Gln 5 10 15 20 gcc cag gtc ccc tct gtc ttc tct ttc gac ttt gca gct gta ctt gtt 152 Ala Gln Val Pro Ser Val Phe Ser Phe Asp Phe Ala Ala Val Leu Val 25 30 35 ttg ctc ctc tac ccg cag gag ctg aca tgg acc caa atc ctc ggg ccg 200 Leu Leu Leu Tyr Pro Gln Glu Leu Thr Trp Thr Gln Ile Leu Gly Pro 40 45 50 ccc tgg agc gcc agc agc tcc gcc ttc ggg agc ggc aaa aat tct tcg 248 Pro Trp Ser Ala Ser Ser Ser Ala Phe Gly Ser Gly Lys Asn Ser Ser 55 60 65 agg aca ttt tac agc cag aga cag agt ttg tct ttc ctc tgt ccc atc 296 Arg Thr Phe Tyr Ser Gln Arg Gln Ser Leu Ser Phe Leu Cys Pro Ile 70 75 80 tgc atc tcg agt cgc aga gac ccc cca 323 Cys Ile Ser Ser Arg Arg Asp Pro Pro 85 90 25 93 PRT Homo sapiens 25 Cys Pro Gly Arg Ser Gln Gly Pro His Cys Trp Asp Ala Gly Cys Ser 1 5 10 15 Gly Ala Pro Gln Ala Gln Val Pro Ser Val Phe Ser Phe Asp Phe Ala 20 25 30 Ala Val Leu Val Leu Leu Leu Tyr Pro Gln Glu Leu Thr Trp Thr Gln 35 40 45 Ile Leu Gly Pro Pro Trp Ser Ala Ser Ser Ser Ala Phe Gly Ser Gly 50 55 60 Lys Asn Ser Ser Arg Thr Phe Tyr Ser Gln Arg Gln Ser Leu Ser Phe 65 70 75 80 Leu Cys Pro Ile Cys Ile Ser Ser Arg Arg Asp Pro Pro 85 90 26 400 DNA Homo sapiens CDS (21)..(398) 26 gaattcgcgg ccgcgtcgac gtc tca aag gct gtt gag cac atc aat aaa act 53 Val Ser Lys Ala Val Glu His Ile Asn Lys Thr 1 5 10 att gcg cct gcc ctg gtt agc aag aaa ctg aac gtc aca gaa caa gag 101 Ile Ala Pro Ala Leu Val Ser Lys Lys Leu Asn Val Thr Glu Gln Glu 15 20 25 aag att gac aaa ctg atg atc gag atg gat gga aca gaa aat aaa tct 149 Lys Ile Asp Lys Leu Met Ile Glu Met Asp Gly Thr Glu Asn Lys Ser 30 35 40 aag ttt ggt gcg aac gcc att ctg ggg gtg tcc ctt gcc gtc tgc aaa 197 Lys Phe Gly Ala Asn Ala Ile Leu Gly Val Ser Leu Ala Val Cys Lys 45 50 55 gct ggt gcc gtt gag aag ggg gtc ccc ctg tac cgc cac atc gct gac 245 Ala Gly Ala Val Glu Lys Gly Val Pro Leu Tyr Arg His Ile Ala Asp 60 65 70 75 ttg gct ggc aac tct gaa gtc atc ctg cca gtc ccg gcg ttc aat gtc 293 Leu Ala Gly Asn Ser Glu Val Ile Leu Pro Val Pro Ala Phe Asn Val 80 85 90 atc aat ggc ggg ttc tca tgc tgc aac aag ctg gcc atg cac gaa gtt 341 Ile Asn Gly Gly Phe Ser Cys Cys Asn Lys Leu Ala Met His Glu Val 95 100 105 cat gat cct ccc agt cgg tgc agc aaa ctt cag gga agc ctg cgc att 389 His Asp Pro Pro Ser Arg Cys Ser Lys Leu Gln Gly Ser Leu Arg Ile 110 115 120 gga aca gag gg 400 Gly Thr Glu 125 27 126 PRT Homo sapiens 27 Val Ser Lys Ala Val Glu His Ile Asn Lys Thr Ile Ala Pro Ala Leu 1 5 10 15 Val Ser Lys Lys Leu Asn Val Thr Glu Gln Glu Lys Ile Asp Lys Leu 20 25 30 Met Ile Glu Met Asp Gly Thr Glu Asn Lys Ser Lys Phe Gly Ala Asn 35 40 45 Ala Ile Leu Gly Val Ser Leu Ala Val Cys Lys Ala Gly Ala Val Glu 50 55 60 Lys Gly Val Pro Leu Tyr Arg His Ile Ala Asp Leu Ala Gly Asn Ser 65 70 75 80 Glu Val Ile Leu Pro Val Pro Ala Phe Asn Val Ile Asn Gly Gly Phe 85 90 95 Ser Cys Cys Asn Lys Leu Ala Met His Glu Val His Asp Pro Pro Ser 100 105 110 Arg Cys Ser Lys Leu Gln Gly Ser Leu Arg Ile Gly Thr Glu 115 120 125 28 683 DNA Homo sapiens CDS (21)..(683) 28 gaattcgcgg ccgcgtcgac gac gaa gac aca gag ggc ttt gga gtc cct cgc 53 Asp Glu Asp Thr Glu Gly Phe Gly Val Pro Arg 1 5 10 cac gac cct ttg cct gac ccc ctc aag gtc ccc cca cca ctg cct gac 101 His Asp Pro Leu Pro Asp Pro Leu Lys Val Pro Pro Pro Leu Pro Asp 15 20 25 cca tcc agc atc tgc atg gtg gac ccc gag atg ctg ccc ccc aag aca 149 Pro Ser Ser Ile Cys Met Val Asp Pro Glu Met Leu Pro Pro Lys Thr 30 35 40 gca cgg caa acg gag aac gtc agc cgc acc cgg aag ccc ctg gcc cgc 197 Ala Arg Gln Thr Glu Asn Val Ser Arg Thr Arg Lys Pro Leu Ala Arg 45 50 55 ccc aac tca cgc gct gcc gcc ccc aaa gcc act cca gtg gct gct gcc 245 Pro Asn Ser Arg Ala Ala Ala Pro Lys Ala Thr Pro Val Ala Ala Ala 60 65 70 75 aaa acc aag ggg ctt gct ggt ggg gac cgt gcc agc cga cca ctc agt 293 Lys Thr Lys Gly Leu Ala Gly Gly Asp Arg Ala Ser Arg Pro Leu Ser 80 85 90 gcc cgg agt gag ccc agt gag aag gga ggc cgg gca ccc ctg tcc aga 341 Ala Arg Ser Glu Pro Ser Glu Lys Gly Gly Arg Ala Pro Leu Ser Arg 95 100 105 aag tcc tca acc ccc aag act gcc act cga ggc ccg tcg ggg tca gcc 389 Lys Ser Ser Thr Pro Lys Thr Ala Thr Arg Gly Pro Ser Gly Ser Ala 110 115 120 agc agc cgg ccc ggg gtg tca gcc acc cca ccc aag tcc ccg gtc tac 437 Ser Ser Arg Pro Gly Val Ser Ala Thr Pro Pro Lys Ser Pro Val Tyr 125 130 135 ctg gac ctg gcc tac ctg ccc agc ggg agc agc gcc cac ctg gtg gat 485 Leu Asp Leu Ala Tyr Leu Pro Ser Gly Ser Ser Ala His Leu Val Asp 140 145 150 155 gag gag ttc ttc cag cgc gtg cgc gcg ctc tgc tac gtc atc agt ggc 533 Glu Glu Phe Phe Gln Arg Val Arg Ala Leu Cys Tyr Val Ile Ser Gly 160 165 170 cag gac cag cgc aag gag gaa ggc atg cgg gcc gtc ctg gac gcg cta 581 Gln Asp Gln Arg Lys Glu Glu Gly Met Arg Ala Val Leu Asp Ala Leu 175 180 185 ctg gcc agc aag cag cat tgg gac cgt gac ctg cag gtg acc ctg atc 629 Leu Ala Ser Lys Gln His Trp Asp Arg Asp Leu Gln Val Thr Leu Ile 190 195 200 ccc act ttc gac tcg gtg gcc atg cat acg tgg tac gca gag acg cac 677 Pro Thr Phe Asp Ser Val Ala Met His Thr Trp Tyr Ala Glu Thr His 205 210 215 gcc cgg 683 Ala Arg 220 29 221 PRT Homo sapiens 29 Asp Glu Asp Thr Glu Gly Phe Gly Val Pro Arg His Asp Pro Leu Pro 1 5 10 15 Asp Pro Leu Lys Val Pro Pro Pro Leu Pro Asp Pro Ser Ser Ile Cys 20 25 30 Met Val Asp Pro Glu Met Leu Pro Pro Lys Thr Ala Arg Gln Thr Glu 35 40 45 Asn Val Ser Arg Thr Arg Lys Pro Leu Ala Arg Pro Asn Ser Arg Ala 50 55 60 Ala Ala Pro Lys Ala Thr Pro Val Ala Ala Ala Lys Thr Lys Gly Leu 65 70 75 80 Ala Gly Gly Asp Arg Ala Ser Arg Pro Leu Ser Ala Arg Ser Glu Pro 85 90 95 Ser Glu Lys Gly Gly Arg Ala Pro Leu Ser Arg Lys Ser Ser Thr Pro 100 105 110 Lys Thr Ala Thr Arg Gly Pro Ser Gly Ser Ala Ser Ser Arg Pro Gly 115 120 125 Val Ser Ala Thr Pro Pro Lys Ser Pro Val Tyr Leu Asp Leu Ala Tyr 130 135 140 Leu Pro Ser Gly Ser Ser Ala His Leu Val Asp Glu Glu Phe Phe Gln 145 150 155 160 Arg Val Arg Ala Leu Cys Tyr Val Ile Ser Gly Gln Asp Gln Arg Lys 165 170 175 Glu Glu Gly Met Arg Ala Val Leu Asp Ala Leu Leu Ala Ser Lys Gln 180 185 190 His Trp Asp Arg Asp Leu Gln Val Thr Leu Ile Pro Thr Phe Asp Ser 195 200 205 Val Ala Met His Thr Trp Tyr Ala Glu Thr His Ala Arg 210 215 220 30 611 DNA Homo sapiens CDS (21)..(611) 30 gaattcgcgg ccgcgtcgac gac aga aga ttt tcg cgt tct gcg ata cca gag 53 Asp Arg Arg Phe Ser Arg Ser Ala Ile Pro Glu 1 5 10 cag ata atc agc tca aca ctg tcc tca cca tca agt aat gcc cca gac 101 Gln Ile Ile Ser Ser Thr Leu Ser Ser Pro Ser Ser Asn Ala Pro Asp 15 20 25 cca tgt gca aag gag act gta ctg agt gcc ctc aaa gag aag aag aag 149 Pro Cys Ala Lys Glu Thr Val Leu Ser Ala Leu Lys Glu Lys Lys Lys 30 35 40 aaa agg aca gtg gag gaa gaa gac caa ata ttc ctt gat ggc cag gaa 197 Lys Arg Thr Val Glu Glu Glu Asp Gln Ile Phe Leu Asp Gly Gln Glu 45 50 55 aat aaa aga agc tgt ctt gtc gac ggt ctc act gat gcc tct tct gca 245 Asn Lys Arg Ser Cys Leu Val Asp Gly Leu Thr Asp Ala Ser Ser Ala 60 65 70 75 ttc aaa gtt cct cga ccc ggg cca gat aca ctc cag ttc aca gtg gat 293 Phe Lys Val Pro Arg Pro Gly Pro Asp Thr Leu Gln Phe Thr Val Asp 80 85 90 gtc ttc cac ttt gct aat gac tcc aga aac atg ata tac atc acc tgc 341 Val Phe His Phe Ala Asn Asp Ser Arg Asn Met Ile Tyr Ile Thr Cys 95 100 105 cac ctg aag gtc acc cta gct gag cag gac cca gat gaa ctc aac aag 389 His Leu Lys Val Thr Leu Ala Glu Gln Asp Pro Asp Glu Leu Asn Lys 110 115 120 gcc tgt tcc ttc agc aag cct tcc aac agc tgg ttc cca gtg gaa ggc 437 Ala Cys Ser Phe Ser Lys Pro Ser Asn Ser Trp Phe Pro Val Glu Gly 125 130 135 ccg gct gac atc tgt caa tgc tgt aac aaa ggt gac tgt ggc act cca 485 Pro Ala Asp Ile Cys Gln Cys Cys Asn Lys Gly Asp Cys Gly Thr Pro 140 145 150 155 agc cat tcc agg agg cag cct cgt gtc gtg agc cag tgg tcc acg tct 533 Ser His Ser Arg Arg Gln Pro Arg Val Val Ser Gln Trp Ser Thr Ser 160 165 170 gct tcc cgt aac cgc agg cat gtg aca gaa gaa gca gat gtc acc gtg 581 Ala Ser Arg Asn Arg Arg His Val Thr Glu Glu Ala Asp Val Thr Val 175 180 185 ggg gcc act gat ctt cct gga cag gag tgg 611 Gly Ala Thr Asp Leu Pro Gly Gln Glu Trp 190 195 31 197 PRT Homo sapiens 31 Asp Arg Arg Phe Ser Arg Ser Ala Ile Pro Glu Gln Ile Ile Ser Ser 1 5 10 15 Thr Leu Ser Ser Pro Ser Ser Asn Ala Pro Asp Pro Cys Ala Lys Glu 20 25 30 Thr Val Leu Ser Ala Leu Lys Glu Lys Lys Lys Lys Arg Thr Val Glu 35 40 45 Glu Glu Asp Gln Ile Phe Leu Asp Gly Gln Glu Asn Lys Arg Ser Cys 50 55 60 Leu Val Asp Gly Leu Thr Asp Ala Ser Ser Ala Phe Lys Val Pro Arg 65 70 75 80 Pro Gly Pro Asp Thr Leu Gln Phe Thr Val Asp Val Phe His Phe Ala 85 90 95 Asn Asp Ser Arg Asn Met Ile Tyr Ile Thr Cys His Leu Lys Val Thr 100 105 110 Leu Ala Glu Gln Asp Pro Asp Glu Leu Asn Lys Ala Cys Ser Phe Ser 115 120 125 Lys Pro Ser Asn Ser Trp Phe Pro Val Glu Gly Pro Ala Asp Ile Cys 130 135 140 Gln Cys Cys Asn Lys Gly Asp Cys Gly Thr Pro Ser His Ser Arg Arg 145 150 155 160 Gln Pro Arg Val Val Ser Gln Trp Ser Thr Ser Ala Ser Arg Asn Arg 165 170 175 Arg His Val Thr Glu Glu Ala Asp Val Thr Val Gly Ala Thr Asp Leu 180 185 190 Pro Gly Gln Glu Trp 195 32 425 DNA Homo sapiens CDS (18)..(425) 32 gaattcgcgg ccgcgtc gac ggc gag ccc tgc ttc tca tgc ctc tac ggc 50 Asp Gly Glu Pro Cys Phe Ser Cys Leu Tyr Gly 1 5 10 aac ggc ccg cac ccg ccg gcc ccg cag ccc tcc agc agg ttc aac gac 98 Asn Gly Pro His Pro Pro Ala Pro Gln Pro Ser Ser Arg Phe Asn Asp 15 20 25 gcg ccc gcg gcc gac aag gag ccc agc gtg gtg cag ttc tgt gag ttc 146 Ala Pro Ala Ala Asp Lys Glu Pro Ser Val Val Gln Phe Cys Glu Phe 30 35 40 gta tct gcc cca gag gtg agc cgc tgg gcg ggg ccc atc atc gat gtc 194 Val Ser Ala Pro Glu Val Ser Arg Trp Ala Gly Pro Ile Ile Asp Val 45 50 55 ctc ctg gac tac gtg ggc aac gtg cag ctc tgc tcg cgg ctg aag gaa 242 Leu Leu Asp Tyr Val Gly Asn Val Gln Leu Cys Ser Arg Leu Lys Glu 60 65 70 75 cac atc gac agc ttt gag gac tgg gcc gtc atc aag gag aag gca gaa 290 His Ile Asp Ser Phe Glu Asp Trp Ala Val Ile Lys Glu Lys Ala Glu 80 85 90 cct cca aga cct ctg gct cac ctt tgc cga ctg cgg gtt cga aag gcc 338 Pro Pro Arg Pro Leu Ala His Leu Cys Arg Leu Arg Val Arg Lys Ala 95 100 105 att ggg aaa tac cgt ata aaa ctc cta gac acc ttg ccg ctc cca ggc 386 Ile Gly Lys Tyr Arg Ile Lys Leu Leu Asp Thr Leu Pro Leu Pro Gly 110 115 120 agg ctg att aga tac ctg aaa tac gag aac acc cag taa 425 Arg Leu Ile Arg Tyr Leu Lys Tyr Glu Asn Thr Gln 125 130 135 33 135 PRT Homo sapiens 33 Asp Gly Glu Pro Cys Phe Ser Cys Leu Tyr Gly Asn Gly Pro His Pro 1 5 10 15 Pro Ala Pro Gln Pro Ser Ser Arg Phe Asn Asp Ala Pro Ala Ala Asp 20 25 30 Lys Glu Pro Ser Val Val Gln Phe Cys Glu Phe Val Ser Ala Pro Glu 35 40 45 Val Ser Arg Trp Ala Gly Pro Ile Ile Asp Val Leu Leu Asp Tyr Val 50 55 60 Gly Asn Val Gln Leu Cys Ser Arg Leu Lys Glu His Ile Asp Ser Phe 65 70 75 80 Glu Asp Trp Ala Val Ile Lys Glu Lys Ala Glu Pro Pro Arg Pro Leu 85 90 95 Ala His Leu Cys Arg Leu Arg Val Arg Lys Ala Ile Gly Lys Tyr Arg 100 105 110 Ile Lys Leu Leu Asp Thr Leu Pro Leu Pro Gly Arg Leu Ile Arg Tyr 115 120 125 Leu Lys Tyr Glu Asn Thr Gln 130 135 34 206 DNA Homo sapiens CDS (102)..(206) 34 gaattcgcgg ccgcgtcgac caccgntccg tggtccccgg gngcgcattn anancgctnc 60 cgncntccan nngtcactga ntgncccggn ccnctgcgnc c gga acc tgn ccc aac 116 Gly Thr Xaa Pro Asn 1 5 tcc tan agc tgg tcc ttg ggg aga cgc ggg tcc cat gan ctg cgg cta 164 Ser Xaa Ser Trp Ser Leu Gly Arg Arg Gly Ser His Xaa Leu Arg Leu 10 15 20 cta ctg ggg agt gcg ctg gtc tgt aag att gtt gga ctc tcg 206 Leu Leu Gly Ser Ala Leu Val Cys Lys Ile Val Gly Leu Ser 25 30 35 35 35 PRT Homo sapiens misc_feature (3)..(3) The ′Xaa′ at location 3 stands for Trp, or Cys. 35 Gly Thr Xaa Pro Asn Ser Xaa Ser Trp Ser Leu Gly Arg Arg Gly Ser 1 5 10 15 His Xaa Leu Arg Leu Leu Leu Gly Ser Ala Leu Val Cys Lys Ile Val 20 25 30 Gly Leu Ser 35 36 302 DNA Homo sapiens CDS (21)..(302) 36 gaattcgcgg ccgcgtcgac ctt gaa cag aag ctg gct ttg gca gaa cgg att 53 Leu Glu Gln Lys Leu Ala Leu Ala Glu Arg Ile 1 5 10 cga ggc cac gtc ctg tca ttg gca cta cag atg tat ggc tgc cgt gtt 101 Arg Gly His Val Leu Ser Leu Ala Leu Gln Met Tyr Gly Cys Arg Val 15 20 25 atc cag aaa gct ctt gag ttt att cct tca gac cag cag aat gag atg 149 Ile Gln Lys Ala Leu Glu Phe Ile Pro Ser Asp Gln Gln Asn Glu Met 30 35 40 gtt cgg gaa cta gat ggc cat gtc ttg aag tgt gtg aaa gat cag aat 197 Val Arg Glu Leu Asp Gly His Val Leu Lys Cys Val Lys Asp Gln Asn 45 50 55 ggc aat cac gtg gtt cag aaa tgc att gaa tgt gta cag ccc cag tct 245 Gly Asn His Val Val Gln Lys Cys Ile Glu Cys Val Gln Pro Gln Ser 60 65 70 75 ttg caa ttt atc atc gat gcg ttt aag gga cag gta ttt gcc tta tcc 293 Leu Gln Phe Ile Ile Asp Ala Phe Lys Gly Gln Val Phe Ala Leu Ser 80 85 90 aca cat cct 302 Thr His Pro 37 94 PRT Homo sapiens 37 Leu Glu Gln Lys Leu Ala Leu Ala Glu Arg Ile Arg Gly His Val Leu 1 5 10 15 Ser Leu Ala Leu Gln Met Tyr Gly Cys Arg Val Ile Gln Lys Ala Leu 20 25 30 Glu Phe Ile Pro Ser Asp Gln Gln Asn Glu Met Val Arg Glu Leu Asp 35 40 45 Gly His Val Leu Lys Cys Val Lys Asp Gln Asn Gly Asn His Val Val 50 55 60 Gln Lys Cys Ile Glu Cys Val Gln Pro Gln Ser Leu Gln Phe Ile Ile 65 70 75 80 Asp Ala Phe Lys Gly Gln Val Phe Ala Leu Ser Thr His Pro 85 90 38 143 DNA Homo sapiens CDS (21)..(143) 38 gaattcgcgg ccgcgtcgac gca gtt cgg gat cat ttg aag aaa gat agt cag 53 Ala Val Arg Asp His Leu Lys Lys Asp Ser Gln 1 5 10 aac aag act tta ctt aaa acc ctg gca gaa ttg tac acc tat gac aag 101 Asn Lys Thr Leu Leu Lys Thr Leu Ala Glu Leu Tyr Thr Tyr Asp Lys 15 20 25 aac tat ggc aat gct ctg gaa ata tac ntt aac att aag aca 143 Asn Tyr Gly Asn Ala Leu Glu Ile Tyr Xaa Asn Ile Lys Thr 30 35 40 39 41 PRT Homo sapiens misc_feature (37)..(37) The ′Xaa′ at location 37 stands for Ile, Val, Leu, or Phe. 39 Ala Val Arg Asp His Leu Lys Lys Asp Ser Gln Asn Lys Thr Leu Leu 1 5 10 15 Lys Thr Leu Ala Glu Leu Tyr Thr Tyr Asp Lys Asn Tyr Gly Asn Ala 20 25 30 Leu Glu Ile Tyr Xaa Asn Ile Lys Thr 35 40 40 293 DNA Homo sapiens CDS (21)..(293) 40 gaattcgcgg ccgcgtcgac cca gat tct aat gcc ata agg ccc cag ctg gtt 53 Pro Asp Ser Asn Ala Ile Arg Pro Gln Leu Val 1 5 10 ccc cat cac aga acc acc cag cag gaa gcc ggg ggt aca atg acc tcg 101 Pro His His Arg Thr Thr Gln Gln Glu Ala Gly Gly Thr Met Thr Ser 15 20 25 gcc aca cag agc gct cgt gct ttc agc aga gcg cct cca cag aca agc 149 Ala Thr Gln Ser Ala Arg Ala Phe Ser Arg Ala Pro Pro Gln Thr Ser 30 35 40 ctg tgg cca gcc ctg ccc tcc agc ctc gag ctg gag ttg ctc cag agg 197 Leu Trp Pro Ala Leu Pro Ser Ser Leu Glu Leu Glu Leu Leu Gln Arg 45 50 55 cag ccc cag cag gcc tcc ctc cac ata gag gtg gct ggg cca att gcc 245 Gln Pro Gln Gln Ala Ser Leu His Ile Glu Val Ala Gly Pro Ile Ala 60 65 70 75 caa aca cgt gag aca cac agg gag ctt tat gtg ttc atc ttc ctg ctt 293 Gln Thr Arg Glu Thr His Arg Glu Leu Tyr Val Phe Ile Phe Leu Leu 80 85 90 41 91 PRT Homo sapiens 41 Pro Asp Ser Asn Ala Ile Arg Pro Gln Leu Val Pro His His Arg Thr 1 5 10 15 Thr Gln Gln Glu Ala Gly Gly Thr Met Thr Ser Ala Thr Gln Ser Ala 20 25 30 Arg Ala Phe Ser Arg Ala Pro Pro Gln Thr Ser Leu Trp Pro Ala Leu 35 40 45 Pro Ser Ser Leu Glu Leu Glu Leu Leu Gln Arg Gln Pro Gln Gln Ala 50 55 60 Ser Leu His Ile Glu Val Ala Gly Pro Ile Ala Gln Thr Arg Glu Thr 65 70 75 80 His Arg Glu Leu Tyr Val Phe Ile Phe Leu Leu 85 90 42 708 DNA Homo sapiens 42 gaattcgcgg ccgcgtcgac catctctgct gagaaagcct accatgaaca gctttctgta 60 gcagagatca ccaatgcttg ctttgagcca gccaaccaga tggtgaaatg tgaccctcgc 120 catggtaaat acatggcttg ctgcctgttg taccgtggtg acgtggttcc caaagatgtc 180 aatgctgcca ttgccaccat caagaccaag cgtaccatcc agtttgtgga ttggtgcccc 240 actggcttca aggttggcat caactaccag cctcccactg tggtgcctgg tggagacctg 300 gccaaggtac agagagctgt gtgcatgctg agcaacacca cagccattgc tgaggcctgg 360 gctcgcctgg accacaagtt tgacctgatg tatgccaaac gtgcctttgt tcactggtac 420 gttggggagg ggatggagga aggtgagttt tcagaggccc gtgaggacat ggctgccctt 480 gagaaggatt atgaggaggt tggtgtggat tctgttgaag gagagggtga ggaagaagga 540 gaggaatact aaagttaaaa cgtcacaaag gtgctgcttt tacagggaag cttattctgt 600 tttaaacatt gaaaagttgt ggtctgatca gttaatttgt atgtagcagt gtatgctctc 660 atatacaatt actgacctat gctctaaaca tgaatgcttt gttacaga 708 43 83 DNA Homo sapiens CDS (21)..(83) 43 gaattcgcgg ccgcgtcgac ggc tgc tta agt ttt gta tgt agt tgg att ttt 53 Gly Cys Leu Ser Phe Val Cys Ser Trp Ile Phe 1 5 10 tgg agt ccg aag gta tcc atc tgc aga aat 83 Trp Ser Pro Lys Val Ser Ile Cys Arg Asn 15 20 44 21 PRT Homo sapiens 44 Gly Cys Leu Ser Phe Val Cys Ser Trp Ile Phe Trp Ser Pro Lys Val 1 5 10 15 Ser Ile Cys Arg Asn 20 45 140 DNA Homo sapiens CDS (21)..(140) 45 naattcgcgg ccgcgtcgac gga ctc ctg agc aga gtg tcg aga tgt cca cag 53 Gly Leu Leu Ser Arg Val Ser Arg Cys Pro Gln 1 5 10 aag gag gat ttg gtg gta cta gca gca gtg atg ccc agc aaa gtc tac 101 Lys Glu Asp Leu Val Val Leu Ala Ala Val Met Pro Ser Lys Val Tyr 15 20 25 agt cgt tnt ggc ctc ggg tca tgg aag aaa tcc gga att 140 Ser Arg Xaa Gly Leu Gly Ser Trp Lys Lys Ser Gly Ile 30 35 40 46 40 PRT Homo sapiens misc_feature (30)..(30) The ′Xaa′ at location 30 stands for Tyr, Cys, Ser, or Phe. 46 Gly Leu Leu Ser Arg Val Ser Arg Cys Pro Gln Lys Glu Asp Leu Val 1 5 10 15 Val Leu Ala Ala Val Met Pro Ser Lys Val Tyr Ser Arg Xaa Gly Leu 20 25 30 Gly Ser Trp Lys Lys Ser Gly Ile 35 40 47 709 DNA Homo sapiens misc_feature (1)..(701) n represents a, c, t or g 47 naattcgcgg ccgcgtcgac ccaggtcttc agccccacgt cccctccctg aacaatccct 60 tctcatgaan ttcagcagtc aanaaatctg cagctggaag taaatgaata aatgttttgt 120 tttcanaaat aaaaaaaaaa nacccgacan aancnanttn ttatgnctac tttgaaanaa 180 cnccnnggga ngacanaann ctgcnaatta aggaaggtga actatgagga aacagtattt 240 tatgggttgc agtacattct taataagtac ttaaaaggta aagtagtaac caaagagaaa 300 atccaggaag ccaaagatgt ctacaaagaa catttccaag atgatgtctt taatgaaaag 360 ggatggaact acattcttga gaagtatgat gggcatcttc caatagaaat aaaagctgtt 420 cctgagggct ttgtcattcc cagaggaaat gttctcttca cggtggaaaa cacagatcca 480 gagtgttact ggcttacaaa ttggattgag actattcttg ttcagtcctg gtatccaatc 540 acagtggcca caaattctag agagcagaag aaaatattgg ccaaatattt gntagaaact 600 tctggtaact tanatggtct ggaatacaag ttacatgatt ttggctacag aggagtctct 660 tcccaagaga ctgctggcat aggagcatct gctcacttgg ntaacttca 709 48 447 DNA Homo sapiens misc_feature (406)..(406) n represents a, c, t or g 48 gaattcgcgg ccgcgtcgac tgctgagcga ggtgatacaa ctgatgcagt atgtcatcta 60 tggaattgcg tcctttttct tcttgtatgg gatcattctg ttggagaagg cttttacacc 120 acaagtgcag tgaaagaact gcacggtgag tttaaaacaa ccgcttgtgg ccgatgcatc 180 agtggaatgt tcgttttcct cacctatgtg cttggagtgg cctggctggg tgtgtttggt 240 ttctcagcgg tgcccgtgtt tatgttctac aacatatggt caacttgtga agtcatcaag 300 tcaccgcaga ccaacgggac cacgggtgtg gagcagatct gtgtggatat ccgacaatac 360 ggtatcattc ctggaatgct ttcccggaaa aatatgtggc tcttgncctg ggagaacatc 420 tgcaacacaa acgaagttct acatgtc 447 49 590 DNA Homo sapiens CDS (21)..(590) 49 gaattcgcgg ccgcgtcgac cag agc ctg ggc ctg ctt gac cag aac ccc cac 53 Gln Ser Leu Gly Leu Leu Asp Gln Asn Pro His 1 5 10 ctg gct cag gag ctg cgg ccc caa atc cag gaa ctc ctc cac tct gaa 101 Leu Ala Gln Glu Leu Arg Pro Gln Ile Gln Glu Leu Leu His Ser Glu 15 20 25 cac ctg ggt ccc agt gaa ttg gaa gcc cct gcc cct ggg ggc agc agc 149 His Leu Gly Pro Ser Glu Leu Glu Ala Pro Ala Pro Gly Gly Ser Ser 30 35 40 gag gac aag ggt ggg ctg cag cct cca gat tcc aag gat gca gac acc 197 Glu Asp Lys Gly Gly Leu Gln Pro Pro Asp Ser Lys Asp Ala Asp Thr 45 50 55 ccc atg acc ctt cca aaa ggg tcc aca gaa caa gat gct gca tcc cct 245 Pro Met Thr Leu Pro Lys Gly Ser Thr Glu Gln Asp Ala Ala Ser Pro 60 65 70 75 gag aaa gag aag atg aac ccg ctg gaa cag tat gag cga aag gtg aat 293 Glu Lys Glu Lys Met Asn Pro Leu Glu Gln Tyr Glu Arg Lys Val Asn 80 85 90 gcg tct gtt cca agg ggt ttc cct ttc cac tca tcg gag att cag agg 341 Ala Ser Val Pro Arg Gly Phe Pro Phe His Ser Ser Glu Ile Gln Arg 95 100 105 gat gag ctg gca cca gct ggg aca ggg gtg tcc cgt gag gct gtg tcg 389 Asp Glu Leu Ala Pro Ala Gly Thr Gly Val Ser Arg Glu Ala Val Ser 110 115 120 ggt ctg ctg atc atg gga gcg ggc gga ggc tcc ctc atc gtc ctc tcc 437 Gly Leu Leu Ile Met Gly Ala Gly Gly Gly Ser Leu Ile Val Leu Ser 125 130 135 atg ctg ctc ctg cgc agg aag aag ccc tac ggg gct atc agc cat ggc 485 Met Leu Leu Leu Arg Arg Lys Lys Pro Tyr Gly Ala Ile Ser His Gly 140 145 150 155 gtg gtg gag gtg gac ccc atg ctg acc ctg gag gag cag cag ctc cgc 533 Val Val Glu Val Asp Pro Met Leu Thr Leu Glu Glu Gln Gln Leu Arg 160 165 170 gaa ctg cag cgg cac ggc tat gag aac ccc act tac cgc ttc ctg gag 581 Glu Leu Gln Arg His Gly Tyr Glu Asn Pro Thr Tyr Arg Phe Leu Glu 175 180 185 gaa cga ccc 590 Glu Arg Pro 190 50 190 PRT Homo sapiens 50 Gln Ser Leu Gly Leu Leu Asp Gln Asn Pro His Leu Ala Gln Glu Leu 1 5 10 15 Arg Pro Gln Ile Gln Glu Leu Leu His Ser Glu His Leu Gly Pro Ser 20 25 30 Glu Leu Glu Ala Pro Ala Pro Gly Gly Ser Ser Glu Asp Lys Gly Gly 35 40 45 Leu Gln Pro Pro Asp Ser Lys Asp Ala Asp Thr Pro Met Thr Leu Pro 50 55 60 Lys Gly Ser Thr Glu Gln Asp Ala Ala Ser Pro Glu Lys Glu Lys Met 65 70 75 80 Asn Pro Leu Glu Gln Tyr Glu Arg Lys Val Asn Ala Ser Val Pro Arg 85 90 95 Gly Phe Pro Phe His Ser Ser Glu Ile Gln Arg Asp Glu Leu Ala Pro 100 105 110 Ala Gly Thr Gly Val Ser Arg Glu Ala Val Ser Gly Leu Leu Ile Met 115 120 125 Gly Ala Gly Gly Gly Ser Leu Ile Val Leu Ser Met Leu Leu Leu Arg 130 135 140 Arg Lys Lys Pro Tyr Gly Ala Ile Ser His Gly Val Val Glu Val Asp 145 150 155 160 Pro Met Leu Thr Leu Glu Glu Gln Gln Leu Arg Glu Leu Gln Arg His 165 170 175 Gly Tyr Glu Asn Pro Thr Tyr Arg Phe Leu Glu Glu Arg Pro 180 185 190 51 446 DNA Homo sapiens CDS (117)..(446) 51 gaattcgcgg ccgcgtcgac catgaacgaa agagaagcaa aagtaaggaa cggaagcgaa 60 gtagagacag agaaaggaaa aagagcaaaa gccgtgaaag aaagcgaagt agaagc aaa 119 Lys 1 gag agg cga cgg agc cgc tca aga agt cga gat cga aga ttt aga ggc 167 Glu Arg Arg Arg Ser Arg Ser Arg Ser Arg Asp Arg Arg Phe Arg Gly 5 10 15 cgc tac aga agt cct tac tcc gga cca aaa ttt aac agt gcc atc cga 215 Arg Tyr Arg Ser Pro Tyr Ser Gly Pro Lys Phe Asn Ser Ala Ile Arg 20 25 30 gga aag att ggg ttg cct cat agc atc aaa tta agc aga cga cgt tcc 263 Gly Lys Ile Gly Leu Pro His Ser Ile Lys Leu Ser Arg Arg Arg Ser 35 40 45 cga agc aaa agt cca ttc aga aaa gac aag agc cct gtg aga gaa cct 311 Arg Ser Lys Ser Pro Phe Arg Lys Asp Lys Ser Pro Val Arg Glu Pro 50 55 60 65 att gat aat tta act cct gag gaa aga gat gca agg aca gtc ttc tgt 359 Ile Asp Asn Leu Thr Pro Glu Glu Arg Asp Ala Arg Thr Val Phe Cys 70 75 80 atg cag ctg gcg gca aga att cga cca agg gga ttt gga aga gtt ttt 407 Met Gln Leu Ala Ala Arg Ile Arg Pro Arg Gly Phe Gly Arg Val Phe 85 90 95 ctt tca gta gga aag gnt cga gga tgt gag gat gat ttc 446 Leu Ser Val Gly Lys Xaa Arg Gly Cys Glu Asp Asp Phe 100 105 110 52 110 PRT Homo sapiens misc_feature (103)..(103) The ′Xaa′ at location 103 stands for Asp, Gly, Ala, or Val. 52 Lys Glu Arg Arg Arg Ser Arg Ser Arg Ser Arg Asp Arg Arg Phe Arg 1 5 10 15 Gly Arg Tyr Arg Ser Pro Tyr Ser Gly Pro Lys Phe Asn Ser Ala Ile 20 25 30 Arg Gly Lys Ile Gly Leu Pro His Ser Ile Lys Leu Ser Arg Arg Arg 35 40 45 Ser Arg Ser Lys Ser Pro Phe Arg Lys Asp Lys Ser Pro Val Arg Glu 50 55 60 Pro Ile Asp Asn Leu Thr Pro Glu Glu Arg Asp Ala Arg Thr Val Phe 65 70 75 80 Cys Met Gln Leu Ala Ala Arg Ile Arg Pro Arg Gly Phe Gly Arg Val 85 90 95 Phe Leu Ser Val Gly Lys Xaa Arg Gly Cys Glu Asp Asp Phe 100 105 110 53 496 DNA Homo sapiens misc_feature (1)..(490) n represents a, c, t or g 53 naattcgcgg ccgcgtcgac anaactttgg agctggcctt ggctccacct gaccctgtgt 60 cctgngggnc cacncatgcc ggngctgggg acctgtgtgc actttgnggg gaacacctct 120 atgtcctgga acgcctctgt gtcaacggnc atttcttcca ccggagctgc ttccggtgcc 180 atacctgtga ggccacactg tggccaggng gctacgagca gcacccagga gatggacatt 240 tctactgcct ccagcacctg ccccagacag accacaaagc ggaaggcagc gatagaggcc 300 ctgagagtcc ggtaaagact gaaggcgtgt atgtatattg gngcatggga agaggaagan 360 ggnctngtca aaccancgct ttnctggggg taactgaatg tcntnttcta ctancatgta 420 anctctgnga angcnnggat gcctgnctgc ttacacttnt tgntctctna antatntaaa 480 acacanncan acactg 496 54 668 DNA Homo sapiens misc_feature (1)..(650) n represents a, c, t or g 54 naattcgcgg ccgcgtcgac cgtaaaagcc ccaatcttag caagtgccgg ggaaaagcct 60 gggtcgacct caanctagtt cttctggagc tcaacttctt gccaaccaca aggggaccaa 120 gctgaccaaa cagcagccta attctggccc gngacatact ggagatcggg gcccaatgga 180 gcatcctacg caaggacatc ccctccttcg agcgctacat ggcccagctc aaatgctact 240 actttgatta caaggagcag ctccccgagt cagcctatat gcaccagctc ttgggcctca 300 acctcctctt cctgctgtcc cagaaccggg tggctgagtt ccacacggag ttggagcggc 360 tgcctgccaa ggacatacag accaatgtct acatcaagca cccagtgtcc ctggagcaat 420 acctgatgga gggcagctac aacaaagtgt tcctggccaa gggtaacatc cccgccgaga 480 gctacacctt cttcattgac atcctgctcg acactatcag ggatgagatc gctgggtgca 540 tcgagaaggc ctacgagaaa atccttttca ctgaggccac ccggatcctc ttcttcaaca 600 cacccaaaaa gatgacagac tacgccaaga agcgangggt gggncctggn ccccaacaac 660 tactacag 668 55 389 DNA Homo sapiens 55 gaattgcggc cgcgtcgaca tttggccggg gcctttgtct ctagctgctg cgggagctcc 60 aggtctagtc tttactgctc tgtgtattct gctcctagag gcccagcctc tgtgactccg 120 ttatctgcag gtattgggag atgcacagct aagatgccag gaccacctgg aagcctagaa 180 atgggaccac tgacatttag ggatgtggcc atagaattct ctctggagga gtggcaatgc 240 ctggacactg cacaacggaa tttatatagg aaagtgatgt ttgagaacta cagaaacctg 300 gtcttcctgg gtattgctgt ctctaagcct cacctgataa cctgtttgga gcaaggaaaa 360 gagccctgga ataggaagag acaggagat 389 56 239 DNA Homo sapiens CDS (21)..(239) 56 gaatcgcggc cgcgtcgacg cag cag aca ccc atc cca gat cct gtc gag gtg 53 Gln Gln Thr Pro Ile Pro Asp Pro Val Glu Val 1 5 10 agg cct ggg cga gtg gat gga cgt cac aca gag tgt gca gca tgc ttc 101 Arg Pro Gly Arg Val Asp Gly Arg His Thr Glu Cys Ala Ala Cys Phe 15 20 25 ctg ggg gaa ggc cat cga ggc caa aga ccc tca cag ata aag cgg aag 149 Leu Gly Glu Gly His Arg Gly Gln Arg Pro Ser Gln Ile Lys Arg Lys 30 35 40 gtc atg tct ctg cac aca gtc tca ccc ccg cgg ctc aga gtg ccc atc 197 Val Met Ser Leu His Thr Val Ser Pro Pro Arg Leu Arg Val Pro Ile 45 50 55 gcg ggc tcc ttg ggc agt gtt tat ctg ggg cca cgc ccg ctc 239 Ala Gly Ser Leu Gly Ser Val Tyr Leu Gly Pro Arg Pro Leu 60 65 70 57 73 PRT Homo sapiens 57 Gln Gln Thr Pro Ile Pro Asp Pro Val Glu Val Arg Pro Gly Arg Val 1 5 10 15 Asp Gly Arg His Thr Glu Cys Ala Ala Cys Phe Leu Gly Glu Gly His 20 25 30 Arg Gly Gln Arg Pro Ser Gln Ile Lys Arg Lys Val Met Ser Leu His 35 40 45 Thr Val Ser Pro Pro Arg Leu Arg Val Pro Ile Ala Gly Ser Leu Gly 50 55 60 Ser Val Tyr Leu Gly Pro Arg Pro Leu 65 70 58 323 DNA Homo sapiens CDS (21)..(323) 58 gaattcgcgg ccgcgtcgac gga gac agg aag cct caa gtt cca gtg cag aga 53 Gly Asp Arg Lys Pro Gln Val Pro Val Gln Arg 1 5 10 tcc tac ttc tct gag tca gct gac ccc ctc ccc gca atc cct caa acc 101 Ser Tyr Phe Ser Glu Ser Ala Asp Pro Leu Pro Ala Ile Pro Gln Thr 15 20 25 ttg agg aga agt ggg gac ccc acc cct cat cag gag ttc cag tgc tgc 149 Leu Arg Arg Ser Gly Asp Pro Thr Pro His Gln Glu Phe Gln Cys Cys 30 35 40 atg cga tta tct acc cac gtc cac gcg gcc acc tca ccc tct ccg cac 197 Met Arg Leu Ser Thr His Val His Ala Ala Thr Ser Pro Ser Pro His 45 50 55 acc tct ggc tgt ctt ttt gta ctt ttt gtt cca gag ctg ctt ctg tct 245 Thr Ser Gly Cys Leu Phe Val Leu Phe Val Pro Glu Leu Leu Leu Ser 60 65 70 75 ggt tta ttt agg ttt tat cct tcc ttt tct ttg aga gtt cgt gaa gag 293 Gly Leu Phe Arg Phe Tyr Pro Ser Phe Ser Leu Arg Val Arg Glu Glu 80 85 90 gga agc cag gat tgg gga cct gat gga gag 323 Gly Ser Gln Asp Trp Gly Pro Asp Gly Glu 95 100 59 101 PRT Homo sapiens 59 Gly Asp Arg Lys Pro Gln Val Pro Val Gln Arg Ser Tyr Phe Ser Glu 1 5 10 15 Ser Ala Asp Pro Leu Pro Ala Ile Pro Gln Thr Leu Arg Arg Ser Gly 20 25 30 Asp Pro Thr Pro His Gln Glu Phe Gln Cys Cys Met Arg Leu Ser Thr 35 40 45 His Val His Ala Ala Thr Ser Pro Ser Pro His Thr Ser Gly Cys Leu 50 55 60 Phe Val Leu Phe Val Pro Glu Leu Leu Leu Ser Gly Leu Phe Arg Phe 65 70 75 80 Tyr Pro Ser Phe Ser Leu Arg Val Arg Glu Glu Gly Ser Gln Asp Trp 85 90 95 Gly Pro Asp Gly Glu 100 60 711 DNA Homo sapiens 60 gaattcgcgg ccgcgtcgac cactgctcca gttattatat ttgtttccaa aatgtttgca 60 gttgatgcta aggccttgcc tcagaataag ccaaggcctc tcactcaaga agaaattgct 120 cagagacgtg agcgtgcaag acaaaggcat gcagagaagc ttgcagcagc acagggacag 180 gcacccttgg agcccaccca agatgggagt gccattgaaa catgtccaaa aggagaggag 240 ccaagaggtg acgagcaaca ggtggaaagt atgaccccta aacctgtgct ccaggaagaa 300 aacaaccaag agtcttttat tgcatttgct cgggtgttca gtggtgtggc tcgaagagga 360 aagaaaattt ttgtcttggg gcccaaatac agtcctcttg agtttttacg aagggtacca 420 ttaggcttct cagctccacc agatggcctc ccccaagtcc cccacatggc atactgtgct 480 ctggaaaacc tgtatcttct gatgggaagg gaactggaat atctagagga ggtacctcca 540 ggaaatgtgc taggaatagg aggccttcaa gattttgtgc tgaaatctgc aacactgtgt 600 agcctgccat cctgcccacc atttatacca ctcaacttcg aagccactcc tattgtgaga 660 gttgctgttg aaccaaaaca tccaagtgaa atgcctcagc tcgtaaaagg a 711 61 332 DNA Homo sapiens 61 gaattcgcgg ccgcgtcgac cattcagtct tctagcattt ggagctaggt aatgatattt 60 ttttttctca ccagtcatat ttaccatggt agtaaaagtc ctagccagta cagttaggca 120 aaaataaatg aataaaatgc atatatatcc gggaagagag aaattaaact tcctctattc 180 ataggagata gattctttca tgtagaaaag tgtaaagaaa ttataaaaaa aactcctcgg 240 accaatcagt gagtttagca aggttgcagg gtacaaagtt aatatataaa aatcgattat 300 atgccagcag tgaacaattg gagtttgaaa tt 332 62 709 DNA Homo sapiens CDS (105)..(707) 62 gaattcgcgg ccgcgtcgac ctttgttggg tgagcttgtt tgtgtccctg tgggtggacg 60 tggttggtga ttggcaggat cctggtatcc gctaacaggt caaa atg cag atc ttc 116 Met Gln Ile Phe 1 gtg aaa acc ctt acc ggc aag acc atc acc ctt gag gtg gag ccc agt 164 Val Lys Thr Leu Thr Gly Lys Thr Ile Thr Leu Glu Val Glu Pro Ser 5 10 15 20 gac acc atc gaa aat gtg aag gcc aag atc cag gat aag gaa ggc att 212 Asp Thr Ile Glu Asn Val Lys Ala Lys Ile Gln Asp Lys Glu Gly Ile 25 30 35 ccc ccc gac cag cag agg ctc atc ttt gca ggc aag cag ctg gaa gat 260 Pro Pro Asp Gln Gln Arg Leu Ile Phe Ala Gly Lys Gln Leu Glu Asp 40 45 50 ggc cgt act ctt tct gac tac aac atc cag aag gag tcg acc ctg cac 308 Gly Arg Thr Leu Ser Asp Tyr Asn Ile Gln Lys Glu Ser Thr Leu His 55 60 65 ctg gtc ctg cgt ctg aga ggt ggt atg cag atc ttc gtg aag acc ctg 356 Leu Val Leu Arg Leu Arg Gly Gly Met Gln Ile Phe Val Lys Thr Leu 70 75 80 acc ggc aag acc atc acc ctg gaa gtg gag ccc agt gac acc atc gaa 404 Thr Gly Lys Thr Ile Thr Leu Glu Val Glu Pro Ser Asp Thr Ile Glu 85 90 95 100 aat gtg aag gcc aag atc cag gat aaa gaa ggc atc cct ccc gac cag 452 Asn Val Lys Ala Lys Ile Gln Asp Lys Glu Gly Ile Pro Pro Asp Gln 105 110 115 cag agg ctc atc ttt gca ggc aag cag ctg gaa gat ggc cgc act ctt 500 Gln Arg Leu Ile Phe Ala Gly Lys Gln Leu Glu Asp Gly Arg Thr Leu 120 125 130 tct gac tac aac atc cag aag gag tcg acc ctg cac ctg gtc ctg cgt 548 Ser Asp Tyr Asn Ile Gln Lys Glu Ser Thr Leu His Leu Val Leu Arg 135 140 145 ctg aga ggt ggt atg cag atc ttc gtg aag acc ctg acc ggc aag acc 596 Leu Arg Gly Gly Met Gln Ile Phe Val Lys Thr Leu Thr Gly Lys Thr 150 155 160 atc act ctg gag gtg gag ccc agt gac acc atc gaa aat gtg aag gcc 644 Ile Thr Leu Glu Val Glu Pro Ser Asp Thr Ile Glu Asn Val Lys Ala 165 170 175 180 aag atc caa gat aaa gaa ggc atc ccc ccc gac cag cag agg ctc atc 692 Lys Ile Gln Asp Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg Leu Ile 185 190 195 ttt gca ggc aag cag ct 709 Phe Ala Gly Lys Gln 200 63 201 PRT Homo sapiens 63 Met Gln Ile Phe Val Lys Thr Leu Thr Gly Lys Thr Ile Thr Leu Glu 1 5 10 15 Val Glu Pro Ser Asp Thr Ile Glu Asn Val Lys Ala Lys Ile Gln Asp 20 25 30 Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg Leu Ile Phe Ala Gly Lys 35 40 45 Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr Asn Ile Gln Lys Glu 50 55 60 Ser Thr Leu His Leu Val Leu Arg Leu Arg Gly Gly Met Gln Ile Phe 65 70 75 80 Val Lys Thr Leu Thr Gly Lys Thr Ile Thr Leu Glu Val Glu Pro Ser 85 90 95 Asp Thr Ile Glu Asn Val Lys Ala Lys Ile Gln Asp Lys Glu Gly Ile 100 105 110 Pro Pro Asp Gln Gln Arg Leu Ile Phe Ala Gly Lys Gln Leu Glu Asp 115 120 125 Gly Arg Thr Leu Ser Asp Tyr Asn Ile Gln Lys Glu Ser Thr Leu His 130 135 140 Leu Val Leu Arg Leu Arg Gly Gly Met Gln Ile Phe Val Lys Thr Leu 145 150 155 160 Thr Gly Lys Thr Ile Thr Leu Glu Val Glu Pro Ser Asp Thr Ile Glu 165 170 175 Asn Val Lys Ala Lys Ile Gln Asp Lys Glu Gly Ile Pro Pro Asp Gln 180 185 190 Gln Arg Leu Ile Phe Ala Gly Lys Gln 195 200 64 122 DNA Homo sapiens CDS (21)..(122) 64 gaattcgcgg ccgcgtcgac aat atg aag aac agg atg atg tgg aga gta atg 53 Asn Met Lys Asn Arg Met Met Trp Arg Val Met 1 5 10 act ctg gag aag acc aga gtg aat ata ata cag aca cat ctg ctc tgt 101 Thr Leu Glu Lys Thr Arg Val Asn Ile Ile Gln Thr His Leu Leu Cys 15 20 25 ctt cta tta atc cag atg aaa 122 Leu Leu Leu Ile Gln Met Lys 30 65 34 PRT Homo sapiens 65 Asn Met Lys Asn Arg Met Met Trp Arg Val Met Thr Leu Glu Lys Thr 1 5 10 15 Arg Val Asn Ile Ile Gln Thr His Leu Leu Cys Leu Leu Leu Ile Gln 20 25 30 Met Lys 66 209 DNA Homo sapiens CDS (21)..(209) 66 gaattcgcgg ccgcgtcgac agg agg gac ccg gag ttg ccc gtc acg tcc ttc 53 Arg Arg Asp Pro Glu Leu Pro Val Thr Ser Phe 1 5 10 gac tgc gcc gtg tgc ctt gag gtg tta cac cag cct gtc cgg acc cgc 101 Asp Cys Ala Val Cys Leu Glu Val Leu His Gln Pro Val Arg Thr Arg 15 20 25 tgt ggc cac ngt att ctg ccg ttc ctg tat tgc tac cag tct aaa gaa 149 Cys Gly His Xaa Ile Leu Pro Phe Leu Tyr Cys Tyr Gln Ser Lys Glu 30 35 40 caa caa gtg gac ctg tcc tta ttg ccg ggc ata tct tcc ttc aga agg 197 Gln Gln Val Asp Leu Ser Leu Leu Pro Gly Ile Ser Ser Phe Arg Arg 45 50 55 agt tcc agc aac 209 Ser Ser Ser Asn 60 67 63 PRT Homo sapiens misc_feature (31)..(31) The ′Xaa′ at location 31 stands for Ser, Gly, Arg, or Cys. 67 Arg Arg Asp Pro Glu Leu Pro Val Thr Ser Phe Asp Cys Ala Val Cys 1 5 10 15 Leu Glu Val Leu His Gln Pro Val Arg Thr Arg Cys Gly His Xaa Ile 20 25 30 Leu Pro Phe Leu Tyr Cys Tyr Gln Ser Lys Glu Gln Gln Val Asp Leu 35 40 45 Ser Leu Leu Pro Gly Ile Ser Ser Phe Arg Arg Ser Ser Ser Asn 50 55 60 68 709 DNA Homo sapiens misc_feature (705)..(705) n represents a, c t or g 68 gaattcgcgg ccgcgtcgac cttttggttt atatatattt tttttaatac ctcagtgctg 60 caagtatcac cagagaggct atggaagaat ttttttttaa tttattgtag atgtaaacag 120 aattttaaaa ataaaaagta taaacatcac tgcacttgtg actggtggga aaaactgaca 180 gtttcctctt tgcacatgtt taacatttgg ctgttataat atatggtcct cggttgggga 240 aagatactta tgatgaagga tattttttaa tttaactttt ttttaaatat tggtaatagg 300 tcggcaacag caactataga agtacaactc aatagatggc attaaaacat attgtagtgt 360 ggatatatat tttttctttt ttaaaatgtg atattgacgt tttattaata ttttttaaat 420 tgttacgttt ataaatttgg tacttaaggc acagccagta tgagacactg aatgcgacat 480 ttattataaa gagctgctgc actcctattt ttataaattt tactaacaaa gtagactaat 540 gtagacattc acagacatgg tagggcaaaa gcatcttcaa actaaagact ccaaaatgct 600 aactcagaaa gaaagaaaaa acccgttttc aattctaatg aaacagcacc accatttttt 660 ttaattaaaa aaaaaaacat ggtctttggt tttctaaaaa aaggnaggg 709 69 706 DNA Homo sapiens 69 gaattcgcgg ccgcgtcgac ctgagctgaa ctgcagctgg gtgcacctgg acctgggcag 60 tgatgtggcc cagcccctcc tgactctgcc tggcacagcc tgtggccctg gcctggtgtg 120 tatagaccat cgatgccagc gtgtggatct cctgggggca caggaatgtc gaagcaaatg 180 ccatggacat ggggtctgtg acagcaacag gcactgctac tgtgaggagg gctgggcacc 240 ccctgactgc accactcagc tcaaagcaac cagctccctg accacagggc tgctcctcag 300 cctcctggtc ttattggtcc tggtgatgct tggtgccagc tactggtacc gtgcccgcct 360 gcaccagcga ctctgccagc tcaagggacc cacctgccag tacagtctca ggggccagcc 420 aagcccccac ccccaaggaa gccactgcct gccgaccccc agggccggtg cccatcgggt 480 gacctgcccg gcccaggggc tggaatcccg cccctagtgg taccctccag accagcgcca 540 ccgcctccga cagtgtcctc gctctacctc tgacctctcc ggaggttccg ctgcctccaa 600 gccggactta gggcttcaag aggcgggcgt gccctctgga gtcccctacc atgactgaag 660 gcgccagaga ctggcggtgt cttaagactc cgggcaccgc cacgcg 706 70 116 DNA Homo sapiens CDS (21)..(116) 70 gaattcgcgg ccgcgtcgac gag aaa ttt gca cct aag aaa cag ggc gat ggt 53 Glu Lys Phe Ala Pro Lys Lys Gln Gly Asp Gly 1 5 10 ggt aag gac ctc ccc acg gaa gca aag aag cgt gca gct gaa ttc tgc 101 Gly Lys Asp Leu Pro Thr Glu Ala Lys Lys Arg Ala Ala Glu Phe Cys 15 20 25 aga gga gct cta tgc 116 Arg Gly Ala Leu Cys 30 71 32 PRT Homo sapiens 71 Glu Lys Phe Ala Pro Lys Lys Gln Gly Asp Gly Gly Lys Asp Leu Pro 1 5 10 15 Thr Glu Ala Lys Lys Arg Ala Ala Glu Phe Cys Arg Gly Ala Leu Cys 20 25 30 72 254 DNA Homo sapiens CDS (21)..(254) 72 gaattcgcgg ccgcgtcgac gtg gct tca ccg ccg gtc cct tgc agc gct gcc 53 Val Ala Ser Pro Pro Val Pro Cys Ser Ala Ala 1 5 10 ttt cga tct ctc cac atc tcg gtg gcg cgg gat ctc aag atg cgc ctc 101 Phe Arg Ser Leu His Ile Ser Val Ala Arg Asp Leu Lys Met Arg Leu 15 20 25 cac ctg ctc ctg ctg ctc gcg ctg tgc ggt gca ggc acc acc gcc gcg 149 His Leu Leu Leu Leu Leu Ala Leu Cys Gly Ala Gly Thr Thr Ala Ala 30 35 40 gag ctc agt tac agc ttg cgt ggc aac tgg agc atc tgc aat ggg aac 197 Glu Leu Ser Tyr Ser Leu Arg Gly Asn Trp Ser Ile Cys Asn Gly Asn 45 50 55 ggc tcg ctg gag ctg ccc ggg gcg gtc cct ggc tgc gtg cac agc gcc 245 Gly Ser Leu Glu Leu Pro Gly Ala Val Pro Gly Cys Val His Ser Ala 60 65 70 75 ttg ttc cag 254 Leu Phe Gln 73 78 PRT Homo sapiens 73 Val Ala Ser Pro Pro Val Pro Cys Ser Ala Ala Phe Arg Ser Leu His 1 5 10 15 Ile Ser Val Ala Arg Asp Leu Lys Met Arg Leu His Leu Leu Leu Leu 20 25 30 Leu Ala Leu Cys Gly Ala Gly Thr Thr Ala Ala Glu Leu Ser Tyr Ser 35 40 45 Leu Arg Gly Asn Trp Ser Ile Cys Asn Gly Asn Gly Ser Leu Glu Leu 50 55 60 Pro Gly Ala Val Pro Gly Cys Val His Ser Ala Leu Phe Gln 65 70 75 74 554 DNA Homo sapiens CDS (276)..(554) 74 gaattcgcgg ccgcgtcgac gagacattaa aatgtccaga ggtagctggt gtgaaaaagt 60 tatatcgttg ccttcagtgt aatagttttg gaagcacttg gtgagaaaac ctaaagttga 120 cgttttcttg gggagaaacg atctccacta ttagggtgaa aaataaggag tcttctagaa 180 aaggccttgg ggtgtgttat gtaagaaata ctaagtcagt tcactgtttc caggcttttc 240 ttacgaaagt taacagccac agctcttttt ggagc ata aat gct gag ctt ttc 293 Ile Asn Ala Glu Leu Phe 1 5 cta aac tct gaa aca ctt ggc aac ctc tca gtc ttg cta aca gct att 341 Leu Asn Ser Glu Thr Leu Gly Asn Leu Ser Val Leu Leu Thr Ala Ile 10 15 20 ttt ttt tta ttt tgt ttt ctt ttc caa atc cct ggc ata ctg ctg aaa 389 Phe Phe Leu Phe Cys Phe Leu Phe Gln Ile Pro Gly Ile Leu Leu Lys 25 30 35 tct ggc tgc tgc cgc ccc tgg ana nac ncc cgt ctg ctg ggg gag tca 437 Ser Gly Cys Cys Arg Pro Trp Xaa Xaa Xaa Arg Leu Leu Gly Glu Ser 40 45 50 ggc tgg ggt acc tgc cag cgc tca cgg gct gng cca ctc cag gca ggc 485 Gly Trp Gly Thr Cys Gln Arg Ser Arg Ala Xaa Pro Leu Gln Ala Gly 55 60 65 70 tca aca act act tca aaa can aaa gcg gct gta att cac aat tca gcc 533 Ser Thr Thr Thr Ser Lys Thr Lys Ala Ala Val Ile His Asn Ser Ala 75 80 85 cac tac agg cac cga tac gtt 554 His Tyr Arg His Arg Tyr Val 90 75 93 PRT Homo sapiens misc_feature (46)..(46) The ′Xaa′ at location 46 stands for Lys, Arg, Thr, or Ile. 75 Ile Asn Ala Glu Leu Phe Leu Asn Ser Glu Thr Leu Gly Asn Leu Ser 1 5 10 15 Val Leu Leu Thr Ala Ile Phe Phe Leu Phe Cys Phe Leu Phe Gln Ile 20 25 30 Pro Gly Ile Leu Leu Lys Ser Gly Cys Cys Arg Pro Trp Xaa Xaa Xaa 35 40 45 Arg Leu Leu Gly Glu Ser Gly Trp Gly Thr Cys Gln Arg Ser Arg Ala 50 55 60 Xaa Pro Leu Gln Ala Gly Ser Thr Thr Thr Ser Lys Thr Lys Ala Ala 65 70 75 80 Val Ile His Asn Ser Ala His Tyr Arg His Arg Tyr Val 85 90 76 218 DNA Homo sapiens CDS (36)..(218) n represents a, c, t or g 76 gaattcgcgg ccgcgtcgac gtcgacgcgg ccggg tta ggc ctc cag tgg cac 53 Leu Gly Leu Gln Trp His 1 5 gct gat ggc cgc cta act aaa aaa ctc aat ggc ctt gct gat tta gag 101 Ala Asp Gly Arg Leu Thr Lys Lys Leu Asn Gly Leu Ala Asp Leu Glu 10 15 20 gct tgc att aag acg ctt cat ggc caa ggc ttt tct cag cca agt cta 149 Ala Cys Ile Lys Thr Leu His Gly Gln Gly Phe Ser Gln Pro Ser Leu 25 30 35 aca acc ctg act gct ttc agt gtg gag ggg tgc ttg cag gag cat tgt 197 Thr Thr Leu Thr Ala Phe Ser Val Glu Gly Cys Leu Gln Glu His Cys 40 45 50 gta att cta atc cag agc tgg 218 Val Ile Leu Ile Gln Ser Trp 55 60 77 61 PRT Homo sapiens 77 Leu Gly Leu Gln Trp His Ala Asp Gly Arg Leu Thr Lys Lys Leu Asn 1 5 10 15 Gly Leu Ala Asp Leu Glu Ala Cys Ile Lys Thr Leu His Gly Gln Gly 20 25 30 Phe Ser Gln Pro Ser Leu Thr Thr Leu Thr Ala Phe Ser Val Glu Gly 35 40 45 Cys Leu Gln Glu His Cys Val Ile Leu Ile Gln Ser Trp 50 55 60 78 709 DNA Homo sapiens CDS (21)..(707) 78 gaattcgcgg ccgcgtcgac ggg atg cag acc ctc ggc ctt cag cac cgc tgc 53 Gly Met Gln Thr Leu Gly Leu Gln His Arg Cys 1 5 10 cga ggt ggc tac cgg gtc aag gcc agg acg tca tat gtg gat gag act 101 Arg Gly Gly Tyr Arg Val Lys Ala Arg Thr Ser Tyr Val Asp Glu Thr 15 20 25 ctg ttt ggc agc cca gca ggc acc cgg cct acc cca ccg gac ttc gat 149 Leu Phe Gly Ser Pro Ala Gly Thr Arg Pro Thr Pro Pro Asp Phe Asp 30 35 40 ccg ccc tgg gtg gag aag gct aac aga acc aga ggc gtg ggc aag gag 197 Pro Pro Trp Val Glu Lys Ala Asn Arg Thr Arg Gly Val Gly Lys Glu 45 50 55 gca tcg aag gcc ttg ggg gca aag ggg agc tgt gag acc acc ccc tca 245 Ala Ser Lys Ala Leu Gly Ala Lys Gly Ser Cys Glu Thr Thr Pro Ser 60 65 70 75 agg ggc agc acc ccc acc ctc aca cca agg aag aag aac aaa tac aga 293 Arg Gly Ser Thr Pro Thr Leu Thr Pro Arg Lys Lys Asn Lys Tyr Arg 80 85 90 ccc atc agc cac acc ccg tct tac tgt gat gag tcg ctg ttt ggc tcc 341 Pro Ile Ser His Thr Pro Ser Tyr Cys Asp Glu Ser Leu Phe Gly Ser 95 100 105 cga tct gaa ggc gcc agc ttc ggg gcc ccg cgg atg gcg aag ggg gat 389 Arg Ser Glu Gly Ala Ser Phe Gly Ala Pro Arg Met Ala Lys Gly Asp 110 115 120 gcc gca aag ctc cgt gct ctc ttg tgg acg cca cca cct acc ccc agg 437 Ala Ala Lys Leu Arg Ala Leu Leu Trp Thr Pro Pro Pro Thr Pro Arg 125 130 135 ggt agc cac tcg ccc cgc ccc agg gag gca cca ctg cga gcc att cac 485 Gly Ser His Ser Pro Arg Pro Arg Glu Ala Pro Leu Arg Ala Ile His 140 145 150 155 cca gct ggt ccc tcc aag aca gag ccg ggg cca gcg gca gac tcc cag 533 Pro Ala Gly Pro Ser Lys Thr Glu Pro Gly Pro Ala Ala Asp Ser Gln 160 165 170 aag tta tct atg ggt ggg tta cac tct tca cgc ccc ctg aag cgg gga 581 Lys Leu Ser Met Gly Gly Leu His Ser Ser Arg Pro Leu Lys Arg Gly 175 180 185 ctt tcc cat tcc ctc acc cac ctg aat gtc ccc agc act ggt cat cca 629 Leu Ser His Ser Leu Thr His Leu Asn Val Pro Ser Thr Gly His Pro 190 195 200 gcc acc agt gcc ccc cac aca aat ggg cct cag gat ctc ang cct tnc 677 Ala Thr Ser Ala Pro His Thr Asn Gly Pro Gln Asp Leu Xaa Pro Xaa 205 210 215 acg tca ggg gtg acc ttn cgg agc ccc ctg gt 709 Thr Ser Gly Val Thr Xaa Arg Ser Pro Leu 220 225 79 229 PRT Homo sapiens misc_feature (217)..(217) The ′Xaa′ at location 217 stands for Lys, Arg, Thr, or Met. 79 Gly Met Gln Thr Leu Gly Leu Gln His Arg Cys Arg Gly Gly Tyr Arg 1 5 10 15 Val Lys Ala Arg Thr Ser Tyr Val Asp Glu Thr Leu Phe Gly Ser Pro 20 25 30 Ala Gly Thr Arg Pro Thr Pro Pro Asp Phe Asp Pro Pro Trp Val Glu 35 40 45 Lys Ala Asn Arg Thr Arg Gly Val Gly Lys Glu Ala Ser Lys Ala Leu 50 55 60 Gly Ala Lys Gly Ser Cys Glu Thr Thr Pro Ser Arg Gly Ser Thr Pro 65 70 75 80 Thr Leu Thr Pro Arg Lys Lys Asn Lys Tyr Arg Pro Ile Ser His Thr 85 90 95 Pro Ser Tyr Cys Asp Glu Ser Leu Phe Gly Ser Arg Ser Glu Gly Ala 100 105 110 Ser Phe Gly Ala Pro Arg Met Ala Lys Gly Asp Ala Ala Lys Leu Arg 115 120 125 Ala Leu Leu Trp Thr Pro Pro Pro Thr Pro Arg Gly Ser His Ser Pro 130 135 140 Arg Pro Arg Glu Ala Pro Leu Arg Ala Ile His Pro Ala Gly Pro Ser 145 150 155 160 Lys Thr Glu Pro Gly Pro Ala Ala Asp Ser Gln Lys Leu Ser Met Gly 165 170 175 Gly Leu His Ser Ser Arg Pro Leu Lys Arg Gly Leu Ser His Ser Leu 180 185 190 Thr His Leu Asn Val Pro Ser Thr Gly His Pro Ala Thr Ser Ala Pro 195 200 205 His Thr Asn Gly Pro Gln Asp Leu Xaa Pro Xaa Thr Ser Gly Val Thr 210 215 220 Xaa Arg Ser Pro Leu 225 80 249 DNA Homo sapiens 80 gaattcgcgg ccgcgtcgac cgcggccgcg tcgacgagag gctgaggtgg gaggattgct 60 tgagaccagc ctgggcaaca tggtgaaact ctgtctctac agaaaatttt aaaaattagc 120 caagtgtggt ggtgcacacc tgtagtccca gcagctggag aggctgaggc agaaggattg 180 cttgagccca gaggcagagg tttcagtgag ctgagactgc accactggac tccaacctag 240 gtgacagag 249 81 122 DNA Homo sapiens 81 gaattcgcgg ccgcgtcgac ccaggtcttc agccccacgt ccctccctga acaatccctt 60 ctcatgaaat tcagcagtca agaaatctgc agcggaagta aatgaataaa tgttttgttt 120 tc 122 82 613 DNA Homo sapiens misc_feature (495)..(602) n represents a, c t or g 82 gaattcgcgg ccgcgtcgac aatctgggga agaggtttta tttacatttt agggtgggta 60 agaaagccac cttgttacaa attttttaat ttccaaaata atctatatta aatgagggtt 120 tctgatctgt actttgtgtt tagctacctt tttatattta aaaaattaaa aatgaaaatt 180 atgttcttac aagcttaaag cttgatttga tctttgttta aatgccaaaa tgtacttaaa 240 tgagttactt agaatgccat aaaattgcag tttcatgtat gtatataatc atgctcatgt 300 atatttagtt accgtataat gctttctgag tgagttttac tcttaaatca tttggttaaa 360 atcatttggc ttgctgttta ctcccttctg tagtttttaa ttaaaaactt taagataagt 420 ctacattaac aatggatcac atctaaagct ttatctttgg ggaatccaag ttttttggga 480 aaaaccaaaa tgggnnaatt ggcctaantg gaattcaagg ctttnaaagt cantattccg 540 ggctgggtaa gggaatttat gagattacct gctctaaaaa gtataaatgg ncnagggacc 600 gntttggatt gct 613 83 490 DNA Homo sapiens misc_feature (452)..(487) n represents a, c t or g 83 gaattcgcgg ccgcgtcgac gtcccactcc taaacacatc cgtattactc gcatcaggag 60 tatcaatcac ctgagctcac catagtctaa tagaaaacaa ccgaaaccaa ataattcaag 120 cactgcttat tacaatttta ctgggtctct attttaccct cctacaagcc tcagagtact 180 tcgagtctcc cttcaccatt tccgacggca tctacggctc aacatttttt gtagccacag 240 gcttccacgg acttcacgtc attattggct caactttcct cactatctgc ttcatccgcc 300 aactaatatt tcactttaca tccaaacatc actttggctt cgaagccgcc gcctgatact 360 ggcattttgt agatgtggtt tgactatttc tgtatgtctc catctattga tgagggtctt 420 aaaaaaaaaa aaaaaaaaaa aaaaaacccc cnnnaaantt tnnaatngga aaannnnaaa 480 anccccnggg 490 84 592 DNA Homo sapiens misc_feature (487)..(588) n represents a, c t or g 84 accccactca gctcacctct ccctccacct cctctccacc tgctggtgag aggtgcaaag 60 aggcagatct ttgctgccag ccacttcatc ccctcccaga tgttggacca acacccctcc 120 ctgccaccag gcactgcctg gagggcaggg agtgggagcc aatgaacagg catgcaagtg 180 agagcttcct gagctttctc ctgtcggttt ggtctgtttt gccttcaccc ataagcccct 240 cgcactctgg tggcaggtgc cttgtcctca gggctacagc agtagggagg tcagtgcttc 300 gtgcctcgat tgaaggtgac ctctgcccca gataggtggt gccagtggct tattaattcc 360 gatactagtt tgctttgctg accaaatgcc tggtaccaga ggatggtgag gcgaaggcca 420 ggttgggggc agtgttgtgg ccctggggcc cagccccaaa ctgggggctc tgtatatagc 480 tatgaanaaa acacaaagng tataaatctg agtatatatt tacatgtctt tttaaaaggg 540 ncgntaccan anatttaccc atcgnnnaan angctnctgg nggntggnag gc 592 85 536 DNA Homo sapiens 85 catttgtgtt ttagtttctt ttttcatgac tgaagggagt tttatgttat tatttcttcc 60 atagttttgt tttggtttat ttttaacaac gctctagaaa caaagtcaaa ttaatcacaa 120 aagacataat tttgctttgt tgtggaattt ctatttcaac gtcaactctg tatctatgag 180 tatgtctgtt ccacagacag atgaggcagg agtgatgggg cactcaagaa agttcagagg 240 aggcataagc tatggaggtt ggaaaggaag aaagagaaga gctgaagtaa atgtatggta 300 gaaattaaga cgtttctttg caaaacaagg aaatcacaca tatgcacaca tacatattta 360 tggttactat gattgttatt atttgtccaa tcaagcaaag caccattatt tctaacatat 420 aaaagaccag atcaaacaca atggaaataa agctactaca tatatatgcc agtatttctc 480 tagtaagatt atgtttctct tactagaaaa ctattttcta aatattaaca ctgaaa 536 86 688 DNA Homo sapiens misc_feature (683)..(683) n reprsents a, c t or g 86 caaaaggttt gtgtccagga tgtacaaaga actctcaaac cggatagtaa gaaaacaaac 60 agcccaagtg aaaagcaggc aaaagacttg aatagacact tcaccaaaga gcatacacgc 120 gtggcaaaca agcacacgaa aagacgttca gccgccgatg gcttggttat aatttataac 180 ttacttattt ttatctaata attgtagatt cagtgtattt cttcaaaaaa tgtttaatta 240 aatgcatgtt aatggtgagt gaatcccttg ggtgacttcg tgtttaggtc gtattagggc 300 atttgttgga tcaacggatc attttaaccc tgacttcccc ttattcccat aaaagaagtt 360 ttccagtgga atggagattt cattttgtca gcagcagtga ccacagcctt accaaagcag 420 acgcgtgcgc gtgcacagat gcacacacac agatgtctta aaagactaga atccacactt 480 cctgagccag aggggccgtg ttgacggtaa tgcattctct atagagccaa gtccaaactg 540 gcaagctcaa tgatgcaggc aataaaccgc ctttttggca gcctaccaat gccaaaagga 600 taaatgtctt tccaaaagtg tgtattcctg ttaaattaag ctcttgctaa cttgaaaaat 660 ccctgttctg ccagcgaagc ttnctcct 688 87 402 DNA Homo sapiens misc_feature (115)..(183) n represents a, c, t or g 87 cgggccaggg ccacacccaa gggcccagcg tgtcttgcct gcccgtgggc acccacggac 60 gtggcttggt gctgaggata gcagagcccc cagccatcac tgctggcagc ctggncaaac 120 cgggtgagca acaggaggac gaggggcctg gggcggtgcc aggctaccac aagaacctgc 180 gtnttggacc attgcccctc ccggccccaa accacagggg ctcaggtcgt gtgggcccca 240 gtgctagatc tctccctccc ttcgtctctg tctgtgctgt tggcgacccc tctgtctgtc 300 tccagccctg tctttctgtt ctcttatctc tttgtttcac cttttccctc tctggcgtcc 360 ccggctgctt gtactcttgg ccttttctgt gtctcctttc tg 402 88 568 DNA Homo sapiens 88 tatgaatggc tccacgaggg ttcagctgtc tcttactttt aaccagtgaa attgacctgc 60 ccgtgaagag gcgggcatga cacagcaaga cgagaagacc ctatggagct ttaatttatt 120 aatgcaaaca gtacctaaca aacccacagg tcctaaacta ccaaacctgc attaaaaatt 180 tcggttgggg cgacctcgga gcagaaccca acctccgagc agtacatgct aagacttcac 240 cagtcaaagc gaactactat actcaattga tccaataact tgaccaacgg aacaagttac 300 cctagggata acagcgcaat cctattctag agtccatatc aacaataggg tttacgacct 360 cgatgttgga tcaggacatc ccgatggtgc agccgctatt aaaggttcgt ttgttcaacg 420 attaaagtcc tacgtgatct gagttcagac cggagtaatc caggtcggtt tctatctact 480 tcaaattcct ccctgtacga aaggacaaga gaaataaggc ctacttcaca aagcgccttc 540 ccccgtaaat gatatcatct caacttag 568 89 30 DNA Homo sapiens 89 actaacatct ctagtcagcg agctggcaga 30 90 30 DNA Unknown primer 90 ccggaattcg tcacccagtg ccaaagctgt 30 91 49 DNA Unknown primer 91 cgggatcctc tagagcggcc gcttattatt tagcttcctg taacgcccc 49 92 2082 DNA Mus musculus CDS (1)..(2082) 92 gtc acc cag tgc caa agc tgt gtc cag gca gct gga gag gta ggg gta 48 Val Thr Gln Cys Gln Ser Cys Val Gln Ala Ala Gly Glu Val Gly Val 1 5 10 15 ctg acc ggc cac tcc cag aaa tca cgt agg tca ccc ctg gag gag aag 96 Leu Thr Gly His Ser Gln Lys Ser Arg Arg Ser Pro Leu Glu Glu Lys 20 25 30 cag ttg gag gag gag gat tcc tct gcc act tcc gaa gaa gga gga gga 144 Gln Leu Glu Glu Glu Asp Ser Ser Ala Thr Ser Glu Glu Gly Gly Gly 35 40 45 ggg cct ggc cca gaa gct tca ctc aac aag ggc ctg gcc aag cac ctg 192 Gly Pro Gly Pro Glu Ala Ser Leu Asn Lys Gly Leu Ala Lys His Leu 50 55 60 ctg agt ggt ttg ggg gac cga ctc tgc cgc ctg ctg cgg aag gag cgg 240 Leu Ser Gly Leu Gly Asp Arg Leu Cys Arg Leu Leu Arg Lys Glu Arg 65 70 75 80 gag gcc ctt gcc tgg gca cag cga gaa ggc cag ggg cca gcc atg aca 288 Glu Ala Leu Ala Trp Ala Gln Arg Glu Gly Gln Gly Pro Ala Met Thr 85 90 95 gag gac agc cca ggc att cca cat tgc tgc agc cga tgc cac cac gga 336 Glu Asp Ser Pro Gly Ile Pro His Cys Cys Ser Arg Cys His His Gly 100 105 110 ctc ttc aac acc cac tgg aga tgt tcc cac tgt agc cac cgg ctg tgt 384 Leu Phe Asn Thr His Trp Arg Cys Ser His Cys Ser His Arg Leu Cys 115 120 125 gta gcc tgt ggt cgc ata gcc ggt gct gga aag aac agg gag aaa aca 432 Val Ala Cys Gly Arg Ile Ala Gly Ala Gly Lys Asn Arg Glu Lys Thr 130 135 140 ggt tct cag gaa cag cac aca gat gac tgc gcc cag gag gct ggg cat 480 Gly Ser Gln Glu Gln His Thr Asp Asp Cys Ala Gln Glu Ala Gly His 145 150 155 160 gct gcc tgt tcc ctg atc ctg acc cag ttt gtc tcc agc cag gcg ctg 528 Ala Ala Cys Ser Leu Ile Leu Thr Gln Phe Val Ser Ser Gln Ala Leu 165 170 175 gca gaa ctg agc act gtg atg cac caa gtc tgg gcc aag ttt gac att 576 Ala Glu Leu Ser Thr Val Met His Gln Val Trp Ala Lys Phe Asp Ile 180 185 190 cgg ggg cac tgt ttc tgc cag gtt gat gcc cgt gtg tgg gcc ccc ggg 624 Arg Gly His Cys Phe Cys Gln Val Asp Ala Arg Val Trp Ala Pro Gly 195 200 205 gat ggg ggt cag cag aag gaa cca aca gag aaa act ccc cca act cca 672 Asp Gly Gly Gln Gln Lys Glu Pro Thr Glu Lys Thr Pro Pro Thr Pro 210 215 220 caa cct tcc tgc aat gga gat tcc aat cgg acc aag gac atc aaa gaa 720 Gln Pro Ser Cys Asn Gly Asp Ser Asn Arg Thr Lys Asp Ile Lys Glu 225 230 235 240 gag acc cca gac tcc act gag agc cca gca gag gac ggt gct ggc cgg 768 Glu Thr Pro Asp Ser Thr Glu Ser Pro Ala Glu Asp Gly Ala Gly Arg 245 250 255 tca ccc ctt cct tgt ccc tct ctc tgt gag ctg cta gcc tct act gct 816 Ser Pro Leu Pro Cys Pro Ser Leu Cys Glu Leu Leu Ala Ser Thr Ala 260 265 270 gtc aaa ctc tgc ctg ggg cat gac cgg att cac atg gcc ttt gct ccg 864 Val Lys Leu Cys Leu Gly His Asp Arg Ile His Met Ala Phe Ala Pro 275 280 285 gtc acc cca gct ctg ccc agt gat gac cgc att acc aac atc ctg gac 912 Val Thr Pro Ala Leu Pro Ser Asp Asp Arg Ile Thr Asn Ile Leu Asp 290 295 300 agc att att gcg cag gta gta gaa cgg aag atc caa gag aaa gcc ctg 960 Ser Ile Ile Ala Gln Val Val Glu Arg Lys Ile Gln Glu Lys Ala Leu 305 310 315 320 ggg cca ggc ctg cga gca ggg tca ggc tta cgc aag ggc ctg agc ctt 1008 Gly Pro Gly Leu Arg Ala Gly Ser Gly Leu Arg Lys Gly Leu Ser Leu 325 330 335 cca ttg tca cca gtg cga acc cgg ctg tct cct cct gga gct ttg ctg 1056 Pro Leu Ser Pro Val Arg Thr Arg Leu Ser Pro Pro Gly Ala Leu Leu 340 345 350 tgg ctg cag gag cct agg cct aag cat ggc ttc cat ctc ttc cag gaa 1104 Trp Leu Gln Glu Pro Arg Pro Lys His Gly Phe His Leu Phe Gln Glu 355 360 365 cac tgg cgg cag ggc cag ccc gtg tta gtg tca ggc atc cag aag aca 1152 His Trp Arg Gln Gly Gln Pro Val Leu Val Ser Gly Ile Gln Lys Thr 370 375 380 ttg aga ctt agc ctg tgg gga atg gaa gcc ctt ggg aca ctt ggt ggc 1200 Leu Arg Leu Ser Leu Trp Gly Met Glu Ala Leu Gly Thr Leu Gly Gly 385 390 395 400 cag gtg cag aca ctg act gcc ctt ggg cct ccc cag ccc aca aac ctg 1248 Gln Val Gln Thr Leu Thr Ala Leu Gly Pro Pro Gln Pro Thr Asn Leu 405 410 415 gac agc aca gca ttc tgg gag gga ttc tct cat cct gag aca cgt cca 1296 Asp Ser Thr Ala Phe Trp Glu Gly Phe Ser His Pro Glu Thr Arg Pro 420 425 430 aag tta gat gag ggc tct gtc ctc ctg cta cac cga acc ctg ggg gat 1344 Lys Leu Asp Glu Gly Ser Val Leu Leu Leu His Arg Thr Leu Gly Asp 435 440 445 aag gac gct agc agg gtg cag aac ctt gcc tcc agc ctt cca ctc cca 1392 Lys Asp Ala Ser Arg Val Gln Asn Leu Ala Ser Ser Leu Pro Leu Pro 450 455 460 gaa tac tgt gcc cac caa ggg aaa ctc aac cta gcg tcc tac ctc ccc 1440 Glu Tyr Cys Ala His Gln Gly Lys Leu Asn Leu Ala Ser Tyr Leu Pro 465 470 475 480 ctg ggc ctc aca ctg cat cca ctg gag ccc cag ctc tgg gcg gcc tat 1488 Leu Gly Leu Thr Leu His Pro Leu Glu Pro Gln Leu Trp Ala Ala Tyr 485 490 495 ggt gtg aac tca cac cgt gga cac ctg ggg acc aag aat cta tgc gtg 1536 Gly Val Asn Ser His Arg Gly His Leu Gly Thr Lys Asn Leu Cys Val 500 505 510 gag gtg tct gac cta atc agt atc ctg gtg cac gcc gag gcc cag ctg 1584 Glu Val Ser Asp Leu Ile Ser Ile Leu Val His Ala Glu Ala Gln Leu 515 520 525 cct ccc tgg tat cga gca cag aaa gat ttc ctc tca ggc ctg gat ggg 1632 Pro Pro Trp Tyr Arg Ala Gln Lys Asp Phe Leu Ser Gly Leu Asp Gly 530 535 540 gaa gga ctc tgg tct cca ggg agc cag acc agc act gtg tgg cat gtg 1680 Glu Gly Leu Trp Ser Pro Gly Ser Gln Thr Ser Thr Val Trp His Val 545 550 555 560 ttc cgg gcc cag gat gcc cag cgc atc cgt cgc ttt ctc cag atg gtg 1728 Phe Arg Ala Gln Asp Ala Gln Arg Ile Arg Arg Phe Leu Gln Met Val 565 570 575 tgc cca gct gga gca gga acc ttg gag cct ggt gcc cca ggc agc tgc 1776 Cys Pro Ala Gly Ala Gly Thr Leu Glu Pro Gly Ala Pro Gly Ser Cys 580 585 590 tac ttg gat gca ggg ttg cgc cga cgg cta aga gaa gag tgg ggt gtg 1824 Tyr Leu Asp Ala Gly Leu Arg Arg Arg Leu Arg Glu Glu Trp Gly Val 595 600 605 agc tgc tgg acc ctg ctg cag gct cct ggg gaa gcg gtg ctg gtc ccg 1872 Ser Cys Trp Thr Leu Leu Gln Ala Pro Gly Glu Ala Val Leu Val Pro 610 615 620 gct ggg gcg ccc cat cag gtg cag ggc ctg gtg agc aca atc agt gtc 1920 Ala Gly Ala Pro His Gln Val Gln Gly Leu Val Ser Thr Ile Ser Val 625 630 635 640 act cag cac ttt ctg tct cct gag acc tct gcc ctc tct gct cag ctc 1968 Thr Gln His Phe Leu Ser Pro Glu Thr Ser Ala Leu Ser Ala Gln Leu 645 650 655 tac cac cag gga gcc agc cta ccc cct gac cac cgt atg ctt tat gcc 2016 Tyr His Gln Gly Ala Ser Leu Pro Pro Asp His Arg Met Leu Tyr Ala 660 665 670 cag atg gac cgg gct gtg ttc caa gca gta aag gcg gct gtg ggg gcg 2064 Gln Met Asp Arg Ala Val Phe Gln Ala Val Lys Ala Ala Val Gly Ala 675 680 685 tta cag gaa gct aaa tag 2082 Leu Gln Glu Ala Lys 690 93 693 PRT Mus musculus 93 Val Thr Gln Cys Gln Ser Cys Val Gln Ala Ala Gly Glu Val Gly Val 1 5 10 15 Leu Thr Gly His Ser Gln Lys Ser Arg Arg Ser Pro Leu Glu Glu Lys 20 25 30 Gln Leu Glu Glu Glu Asp Ser Ser Ala Thr Ser Glu Glu Gly Gly Gly 35 40 45 Gly Pro Gly Pro Glu Ala Ser Leu Asn Lys Gly Leu Ala Lys His Leu 50 55 60 Leu Ser Gly Leu Gly Asp Arg Leu Cys Arg Leu Leu Arg Lys Glu Arg 65 70 75 80 Glu Ala Leu Ala Trp Ala Gln Arg Glu Gly Gln Gly Pro Ala Met Thr 85 90 95 Glu Asp Ser Pro Gly Ile Pro His Cys Cys Ser Arg Cys His His Gly 100 105 110 Leu Phe Asn Thr His Trp Arg Cys Ser His Cys Ser His Arg Leu Cys 115 120 125 Val Ala Cys Gly Arg Ile Ala Gly Ala Gly Lys Asn Arg Glu Lys Thr 130 135 140 Gly Ser Gln Glu Gln His Thr Asp Asp Cys Ala Gln Glu Ala Gly His 145 150 155 160 Ala Ala Cys Ser Leu Ile Leu Thr Gln Phe Val Ser Ser Gln Ala Leu 165 170 175 Ala Glu Leu Ser Thr Val Met His Gln Val Trp Ala Lys Phe Asp Ile 180 185 190 Arg Gly His Cys Phe Cys Gln Val Asp Ala Arg Val Trp Ala Pro Gly 195 200 205 Asp Gly Gly Gln Gln Lys Glu Pro Thr Glu Lys Thr Pro Pro Thr Pro 210 215 220 Gln Pro Ser Cys Asn Gly Asp Ser Asn Arg Thr Lys Asp Ile Lys Glu 225 230 235 240 Glu Thr Pro Asp Ser Thr Glu Ser Pro Ala Glu Asp Gly Ala Gly Arg 245 250 255 Ser Pro Leu Pro Cys Pro Ser Leu Cys Glu Leu Leu Ala Ser Thr Ala 260 265 270 Val Lys Leu Cys Leu Gly His Asp Arg Ile His Met Ala Phe Ala Pro 275 280 285 Val Thr Pro Ala Leu Pro Ser Asp Asp Arg Ile Thr Asn Ile Leu Asp 290 295 300 Ser Ile Ile Ala Gln Val Val Glu Arg Lys Ile Gln Glu Lys Ala Leu 305 310 315 320 Gly Pro Gly Leu Arg Ala Gly Ser Gly Leu Arg Lys Gly Leu Ser Leu 325 330 335 Pro Leu Ser Pro Val Arg Thr Arg Leu Ser Pro Pro Gly Ala Leu Leu 340 345 350 Trp Leu Gln Glu Pro Arg Pro Lys His Gly Phe His Leu Phe Gln Glu 355 360 365 His Trp Arg Gln Gly Gln Pro Val Leu Val Ser Gly Ile Gln Lys Thr 370 375 380 Leu Arg Leu Ser Leu Trp Gly Met Glu Ala Leu Gly Thr Leu Gly Gly 385 390 395 400 Gln Val Gln Thr Leu Thr Ala Leu Gly Pro Pro Gln Pro Thr Asn Leu 405 410 415 Asp Ser Thr Ala Phe Trp Glu Gly Phe Ser His Pro Glu Thr Arg Pro 420 425 430 Lys Leu Asp Glu Gly Ser Val Leu Leu Leu His Arg Thr Leu Gly Asp 435 440 445 Lys Asp Ala Ser Arg Val Gln Asn Leu Ala Ser Ser Leu Pro Leu Pro 450 455 460 Glu Tyr Cys Ala His Gln Gly Lys Leu Asn Leu Ala Ser Tyr Leu Pro 465 470 475 480 Leu Gly Leu Thr Leu His Pro Leu Glu Pro Gln Leu Trp Ala Ala Tyr 485 490 495 Gly Val Asn Ser His Arg Gly His Leu Gly Thr Lys Asn Leu Cys Val 500 505 510 Glu Val Ser Asp Leu Ile Ser Ile Leu Val His Ala Glu Ala Gln Leu 515 520 525 Pro Pro Trp Tyr Arg Ala Gln Lys Asp Phe Leu Ser Gly Leu Asp Gly 530 535 540 Glu Gly Leu Trp Ser Pro Gly Ser Gln Thr Ser Thr Val Trp His Val 545 550 555 560 Phe Arg Ala Gln Asp Ala Gln Arg Ile Arg Arg Phe Leu Gln Met Val 565 570 575 Cys Pro Ala Gly Ala Gly Thr Leu Glu Pro Gly Ala Pro Gly Ser Cys 580 585 590 Tyr Leu Asp Ala Gly Leu Arg Arg Arg Leu Arg Glu Glu Trp Gly Val 595 600 605 Ser Cys Trp Thr Leu Leu Gln Ala Pro Gly Glu Ala Val Leu Val Pro 610 615 620 Ala Gly Ala Pro His Gln Val Gln Gly Leu Val Ser Thr Ile Ser Val 625 630 635 640 Thr Gln His Phe Leu Ser Pro Glu Thr Ser Ala Leu Ser Ala Gln Leu 645 650 655 Tyr His Gln Gly Ala Ser Leu Pro Pro Asp His Arg Met Leu Tyr Ala 660 665 670 Gln Met Asp Arg Ala Val Phe Gln Ala Val Lys Ala Ala Val Gly Ala 675 680 685 Leu Gln Glu Ala Lys 690 94 33 DNA Unknown primer 94 ctattcgatg atgaagatac cccaccaaac cca 33 

What is claimed is:
 1. A composition comprising a mouse Hrt protein-human interacting partner protein complex wherein the human interacting partner protein comprises a molecule selected from the group consisting of ubiquitous receptor UR, SEQ ID NO:4, MAP1A, SEQ ID NO:8, KIAA0930 protein, SEQ ID NO:13, and monocyte antigen CD14.
 2. A composition comprising a mouse Hrt protein-human interacting partner protein complex wherein the human interacting partner protein is encoded by a nucleic acid comprising SEQ ID NO:11, SEQ ID NO:90, or SEQ ID NO:99.
 3. A composition comprising a mouse Hrt protein-human interacting partner protein complex wherein the human interacting partner protein comprises a molecule selected from the group consisting of sphingolipid activator protein, beta-synuclein, C11 protein, vesicle-associated membrane protein 2, SEQ ID NO:25, aldolase A, CGI-106 protein, hypothalamus protein HSMNP1, alpha enolase, SEQ ID NO:35, POM-ZP3, SEQ ID NO:39, quinone oxidoreductase, SEQ ID NO:43, pumilio 1, VPS41, and KIAA0614 protein.
 4. A composition comprising a mouse Hrt protein-human interacting partner nucleic acid complex wherein the human interacting partner nucleic acid comprises SEQ ID NO:95.
 5. A composition comprising a mouse Hrt protein-human interacting partner protein complex where the human interacting partner protein comprises a molecule selected from the group consisting of SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:58, splicing factor CC1.4, SEQ ID NO:65, SEQ ID NO:67, ubiquitin, beta-mannosidase, SEQ ID NO:85, and SEQ ID NO:87.
 6. A composition comprising a mouse Hrt protein-human interacting partner protein complex wherein the human interacting partner protein is encoded by a nucleic acid comprising SEQ ID NO:50, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:82, SEQ ID NO:88, SEQ ID NO: 89, or SEQ ID NO:91.


7. A composition comprising a mouse Hrt protein-human interacting partner nucleic acid complex wherein the human interacting partner nucleic acid comprises SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, or SEQ ID NO:98.
 8. A method of assaying a test compound for agonist or antagonist activity for the composition of claim 1, comprising: a) measuring a level of interaction between mouse Hrt protein and the human interacting partner protein in the absence of the test compound; b) measuring a level of interaction between mouse Hrt protein and the human interacting partner protein in the presence of the test compound; wherein when the level measured in step b) is greater than the level in step a), the test compound has agonist activity, and wherein when the level measured in step b) is less than the level in step a), the test compound has antagonist activity.
 9. A method of assaying a test compound for agonist or antagonist activity for the composition of claim 2, comprising: a) measuring a level of interaction between mouse Hrt protein and the human interacting partner protein in the absence of the test compound; b) measuring a level of interaction between mouse Hrt protein and the human interacting partner protein in the presence of the test compound; wherein when the level measured in step b) is greater than the level in step a), the test compound has agonist activity, and wherein when the level measured in step b) is less than the level in step a), the test compound has antagonist activity.
 10. A method of assaying a test compound for agonist or antagonist activity for the composition of claim 3, comprising: a) measuring a level of interaction between mouse Hrt protein and the human interacting partner protein in the absence of the test compound; b) measuring a level of interaction between mouse Hrt protein and the human interacting partner protein in the presence of the test compound; wherein when the level measured in step b) is greater than the level in step a), the test compound has agonist activity, and wherein when the level measured in step b) is less than the level in step a), the test compound has antagonist activity.
 11. A method of assaying a test compound for agonist or antagonist activity for the composition of claim 4, comprising: a) measuring a level of interaction between mouse Hrt protein and the human interacting partner nucleic acid in the absence of the test compound; b) measuring a level of interaction between mouse Hrt protein and the human interacting partner nucleic acid in the presence of the test compound; wherein when the level measured in step b) is greater than the level in step a), the test compound has agonist activity, and wherein when the level measured in step b) is less than the level in step a), the test compound has antagonist activity.
 12. A method of assaying a test compound for agonist or antagonist activity for the composition of claim 5, comprising: a) measuring a level of interaction between mouse Hrt protein and the human interacting partner protein in the absence of the test compound; b) measuring a level of interaction between mouse Hrt protein and the human interacting partner protein in the presence of the test compound; wherein when the level measured in step b) is greater than the level in step a), the test compound has agonist activity, and wherein when the level measured in step b) is less than the level in step a), the test compound has antagonist activity.
 13. A method of assaying a test compound for agonist or antagonist activity for the composition of claim 6, comprising: a) measuring a level of interaction between mouse Hrt protein and the human interacting partner protein in the absence of the test compound; b) measuring a level of interaction between mouse Hrt protein and the human interacting partner protein in the presence of the test compound; wherein when the level measured in step b) is greater than the level in step a), the test compound has agonist activity, and wherein when the level measured in step b) is less than the level in step a), the test compound has antagonist activity.
 14. A method of assaying a test compound for agonist or antagonist activity for the composition of claim 7, comprising: a) measuring a level of interaction between mouse Hrt protein and the human interacting partner nucleic acid in the absence of the test compound; b) measuring a level of interaction between mouse Hrt protein and the human interacting partner nucleic acid in the presence of the test compound; wherein when the level measured in step b) is greater than the level in step a), the test compound has agonist activity, and wherein when the level measured in step b) is less than the level in step a), the test compound has antagonist activity.
 15. A method of inhibiting hair growth on a surface in a subject in need thereof, comprising applying to the surface a growth-inhibiting amount of a compound having antagonist activity for the composition of claim 1 for a time sufficient to inhibit hair growth on the surface.
 16. A method of increasing hair growth on a surface in a subject in need thereof, comprising applying to the surface a growth-increasing amount of a compound having agonist activity for the composition of claim 1 for a time sufficient to increase hair growth on the surface.
 17. A method of inhibiting hair growth on a surface in a subject in need thereof, comprising applying to the surface a growth-inhibiting amount of a compound having antagonist activity for the composition of claim 2 for a time sufficient to inhibit hair growth on the surface.
 18. A method of increasing hair growth on a surface in a subject in need thereof, comprising applying to the surface a growth-increasing amount of a compound having agonist activity for the composition of claim 2 for a time sufficient to increase hair growth on the surface. 